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Abstract 
CYP17A1 and CYP19A1 are the key cytochromes P450 involved in steroidogenesis. Mutations causing 
hypo- or hyper-activation of both these enzymes results in diseased states, including cancers. In 
addition to carrying out mono-oxygenation reactions, both CYP17A1 and CYP19A1 also catalyze 
carbon-carbon lyase reactions. There is significant interest in developing therapeutics capable of 
specifically targeting the CYP17A1 lyase reaction to target androgen synthesis without impacting 
glucocorticoid production, and understanding of CYP19A1 reaction mechanism could similarly help 
guide design of mechanism based inhibitors for certain breast cancers. To interrogate mechanistic 
aspects of both these enzymes, I used Nanodisc technology for reconstituting active forms of these 
proteins in functional complexes with their effector proteins in a native-like membrane environment. 
Cytochrome P450 17A1 (CYP17A1) is a multi-functional enzyme, catalyzing synthesis of glucocorticoid 
precursors by hydroxylation of pregnene nucleus, and androgen biosynthesis by a second C-C lyase 
step, at the expense of glucocorticoid production. It has been recently confirmed in our lab that when 
17-hydroxy-pregnenolone is a substrate, CYP17A1 lyase reaction proceeds through a non-
conventional hemiketal intermediate. However, it remains unknown if the alternate substrate, 17-
hydroxy-progesterone (OH-PROG) is transformed to androstenedione via this novel mechanism, by 
the traditional compound I (Cpd I) mechanism, or by a combination of the two. To this end, I investigated 
kinetic solvent isotope effects on steady state turnover for lyase reaction on OH-PROG. Further, cryo-
trapped peroxo-anion intermediate was spectroscopically followed as the samples were thermally 
annealed. Resonance Raman spectroscopy (rR) on the trapped intermediate was also performed. Our 
results strongly indicate that the CYP17A1 mediated OH-PROG lyase proceeds through a hemiketal 
intermediate.  
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Cytochrome b5 (cyt b5) is a small heme-protein, known to enhance the rate of the CYP17A1 lyase 
reaction by ~5 fold, while having little effect on hydroxylation. Investigation with a redox inactive form 
of cyt b5 indicated that for lyase enhancement, cyt b5 critically requires a redox effector role. In order to 
investigate the electron transfer by cyt b5 to CYP17A1, I employed stopped flow spectroscopy and 
compared the CYP17A1 reduction rates by cyt b5 that by cytochrome P450 reductase (CPR). rR was 
also performed on CYP17A1—cyt b5 complex investigate any conformational perturbations. Taken 
together, our results suggest that cyt b5 critically requires a redox transfer role is essential to enhance 
lyase reaction, and it reduces CYP17A1 oxy-complex ~10fold faster than CPR. rR on oxyferrous 
CYP17A1—cyt b5 complex indicated subtle conformational changes in the active site, which were 
heavily dependent on the identity of the substrate. 
CYP19A1 produces estrogens in a three-step reaction, the first two being hydroxylation steps, while 
the third step comprises a lyase step. The hydroxylation reactions are expected to proceed through the 
conventional Cpd I intermediate, but the active intermediate for the lyase step is not known. We 
investigated kinetic solvent isotope effects on the steady state turnover for the three-step reaction, and 
our results suggest that CYP19A1 lyase chemistry, unlike CYP17A1, proceeds through the Cpd I 
intermediate.  
My thesis is a mechanistic study of the androgenic CYP17A1 and the estrogenic CYP19A1. I 
investigated the active intermediates in the final lyase step by employing various biochemical and 
biophysical techniques to Nanodisc reconstituted enzymes. While CYP19A1 lyase step is suggested 
to proceed through the Cpd I intermediate, in the case of CYP17A1 lyase reaction, a hemiketal 
intermediate is implicated. Furthermore, the biological regulator of androgen synthesis, cyt b5, acts as 
a faster redox donor than CPR in the lyase reaction cycle, and also exerts subtle conformational 
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Hormone biosynthesis in humans is a complicated process involving a series of steps catalyzed by 
multiple enzymes, with the final hormone levels being a result of a delicate balance between 
androgens and estrogens. The hormone biosynthetic pathway involves multiple steps catalyzed by 
various enzymes, most important of them being the cytochrome P450 (CYP) enzymes. These are 
oxygenases which can efficiently catalyze a variety of difficult biotransformation reactions 
(Guengerich, 2001). The first P450 crystal structure was solved in 1987, of the bacterial CYP101, and 
the growing structural information of many P450s over the past ~30 years (DeVore and Scott, 2012; 
Ghosh et al., 2010; De Montellano, 2015; Poulos et al., 1987) has helped immensely in furthering the 
understanding of the catalytic active site, the orientation of substrates and in providing reasonable 
hypotheses regarding the orientation of these proteins in the membranes. Mechanism of the complex 
catalysis by these heme-proteins have been long studied, on P450s ranging from the soluble bacterial 
CYP101 to the complex membrane bound mammalian P450s. Understanding of the mechanistic 
intermediates formed during androgen biosynthesis is essential to inform specific mechanism based 
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inhibitors for targeting hyper-production of androgens in pathogenic states like castration resistant 
prostate cancer and polycystic ovarian syndrome (PCOS). A better understanding of the mechanism 
of estrogen synthesis is expected to guide development of mechanism based inhibitors for targeting 
excessive hormone synthesis in estrogen dependent breast cancer patients. Some P450s are also 
known to be modulated by the association of specific effector proteins, with the androgenic reaction 
by CYP17A1 being affected by association with a small heme-protein cytochrome b5 (cyt b5). 
Information about this interaction is expected to guide development of specific therapeutics targeting 
androgen production with minimal off-target effects.  
This study is a compilation of investigation of the mechanism of androgenic product androstenedione 
synthesis by CYP17A1 and of cyt b5 mediated modulation of CYP17A1 catalyzed androgen synthesis. 
It has been shown previously that the presence of a stable membrane anchor is crucial in the study of 
these membrane associated enzyme complexes (Holmans et al., 1994; Sergeev et al., 2014). 
Therefore, throughout the course of this study, Nanodisc technology was employed to generate 
functional complexes of these enzymes associated with a native-like lipid bilayer. A short study on the 
nature of the mechanistic intermediate in CYP19A1 catalyzed estrogen synthesis was also performed, 
which provides a beautiful contrast between the two enzymes and makes one marvel at the marked 
diversity in the mechanistic aspects of two closely related enzymes, that have evolved to perform such 
different chemistries. In addition to providing insight towards design of specific mechanism based 
inhibitors, this study also hopes to guide development of therapeutic inhibitors of cyt b5–CYP17A1 
interaction, for improving prognosis in castration resistant prostate cancer patients as well as in 
females suffering from polycystic ovarian syndrome.  
 
1.2 Cytochromes P450 
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1.2.1. Introduction: 
Cytochromes P450 (CYPs, P450s) are ubiquitous heme-protein enzymes, found in organisms ranging 
from archaea and viruses to higher eukaryotes. They have been the subject of tremendous interest 
over many decades owing to their efficient catalysis of unusually difficult reactions including alkane 
hydroxylation, heteroatom oxidation, epoxidation, N-dealkylation etc. (Guengerich, 2001). P450s 
belong to a superfamily of >300,000 sequenced members (Nelson, 2017), amd despite having less 
than 20% sequence homology across the gene superfamily, these proteins have a common overall 
fold. In addition to their role in xenobiotic detoxification, their involvement in steroidogenic pathways 
has been the center of great attention. P450s contain one heme, an iron (III) protoporphyrin IX center 
coordinated to an axial cysteine thiolate. They are known to catalyze hydroxylations of alkane carbons 
and epoxidation of alkenes, by efficiently providing an “active oxygen” (De Montellano, 2015). In terms 
of drug metabolism, this increase in polarity of the substrates contributes to the first step in the 
clearance from the body. In addition to the conventional hydroxylation reactions, the steroidogenic 
P450s like CYP51, CYP11A1, CYP17A1 and CYP19A1 also catalyze acyl-carbon bond cleavage 
reactions in the same active site.  
In contrast to the soluble P450s in bacteria, mammalian P450s are membrane associated, mostly with 
endoplasmic reticulum, although some P450s involved in steroid, sterol and bile acid synthesis are 
located in the inner membrane of mitochondria. The enzyme has a 30-50 amino acid long N terminal 
polypeptide chain involved in membrane interaction, followed by a catalytic domain. The active site is 
created by three parallel D, L and I helices and an antiparallel E helix. As compared to bacterial P450s, 
eukaryotic CYP enzymes have a longer region between F and G helices, that makes F’ and G’ helices. 
This region, together with the proline rich N-terminal region and A helix forms a hydrophobic surface 
near the membrane (Williams et al., 2000). The interaction of F and G helices with the membrane 
possibly promotes the transfer of hydrophobic substrates from the membrane to the P450. The P450 
heme iron is connected via a thiolate linkage to a highly-conserved cysteine residue which is housed 
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in a b-bulge preceding the L-helix. This rigid architecture helps protect the Cys and hold it in place to 
accept hydrogen bonds from peptide NH- group. Studies with model porphyrins have shown that this 
axial ligand is the origin of the characteristic 450 nm Soret absorption of carbon monoxide adducts of 
P450s (Collman and Sorrell, 1975). In resting state, the sixth axial ligand position for heme iron is 
occupied by a water molecule which is responsible for its low spin state (S=1/2).  
In one productive reaction cycle, a P450 molecule consumes two reducing equivalents in the form of 
NAD(P)H, which are provided by the associated redox partners. Bacterial and eukaryotic mitochondrial 
P450s associate with a short electron transfer chain of two proteins, an FAD-containing NADH-
putidaredoxin reductase/adrenodoxin reductase and an iron sulfur ferredoxin, called 
putidaredoxin/adrenodoxin. The reductase receives two electrons as hydride from NAD(P)H and 
delivers these as single reducing equivalents to two molecules of the ferredoxin, which is responsible 
for reduction of the associated P450 enzyme. Microsomal P450s, on the other hand, interact with a 
single enzyme called cytochrome P450 reductase (CPR), which is a membrane bound diflavin protein. 
CPR has a hydrophobic N terminal domain which is associated with the membrane, and the two flavin 
containing domains linked together via a linker region. CPR catalyzes the transfer of two electrons 
sequentially from NADPH via its flavin cofactors to P450s and other acceptor proteins as: 
  NAD(P)H              FAD              FMN              P450 
In addition to CPR, some P450s are known to interact with other effector proteins that can affect 
catalysis. One of such proteins is a small heme-protein, Cytochrome b5 (cyt b5). It is a ~17kD 
membrane associated protein which is known to interact with many P450s, including the drug 
metabolizing CYP2B4, 2B6, 2C9, 2C19, 2E1, 3A4, and the steroidogenic CYP17A1. Cyt b5 may 
stimulate or inhibit the P450 mediated catalysis depending on the P450 isozyme, experimental 
conditions and the substrate. For instance, CYP2B4 catalyzed metabolism of the anesthetic 
methoxyflurane is highly enhanced by the presence of cyt b5, whereas the reaction with 
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benzphetamine is not affected at all (Canova-davis and Waskell, 1984). Cyt b5 null mice have been 
shown to have significant changes in metabolism of various substrates, while hepatic deletion of cyt 
b5 showed decreased activity of CYP3A and 2C families (Finn et al., 2008; McLaughlin et al., 2010). 
Another highly conserved region in P450s structure is a portion of I helix near the heme iron. Thr 252 
in CYP101A1 is involved in a local distortion in the I helix in a manner such that its side chain hydroxyl 
group forms a hydrogen bond with a peptide carbonyl oxygen that would normally form a hydrogen 
bond with the backbone NH- group. This distortion has been seen to be significant for proton delivery 
to the heme Fe–OO adduct, causing scission of O–O linkage resulting in the formation of the reactive 
Fe–O intermediate. The acid-alcohol pair in I-helix has been identified to be composed of Asp251 and 
Thr252 in CYP101A1. Mutagenesis studies of this acid-alcohol pair have verified their role in proton 
delivery to the heme. T252A mutant was shown to have completely uncoupled pyridine nucleotide 
reduction, whereas D251N mutant had a 20-fold slower turnover with the second proton transfer 
becoming the rate determining step (Gerber and Sligar, 1994; Makris et al., 2002). It has been 
suggested that the ordered solvent at the active site serves as the direct proton donor to the iron-oxy 
adduct (Benson et al., 1997; Vidakovic et al., 1998). 
 
1.2.2. Reactive intermediates in P450 catalysis: 
Seminal studies with oxygen isotopes in the 1950s demonstrated that the oxygen incorporated by 
P450s comes from atmospheric O2 and not water (Hayaishi et al., 1955; Hayano et al., 1955). P450s 
function by activating molecular oxygen and incorporating one of the oxygen atoms into a wide variety 
of substrates, while the other oxygen atom is converted to water. Information about the reaction 
intermediates has been the fruit of major efforts with various spectroscopic techniques, judiciously 
labelled diagnostic substrates and by studies with synthetic metalloporphyrins (Denisov et al., 2005a; 
Mak and Denisov, 2017; De Montellano, 2015).  
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The canonical P450 reaction cycle is depicted in Figure 1.1 and it starts with the resting state of the 




Figure 1.1: P450 catalytic cycle  
(Denisov et al., 2005a) 
Upon substrate binding, the water molecule gets partially or completely displaced, resulting in the 
formation of a ferric high spin heme iron (S=5/2). Substrate binding also makes the redox potential of 
the heme iron more positive (by 100-130mV), which then gets reduced by an associated redox partner, 
cytochrome P450 reductase (CPR) for microsomal P450s, and results in the formation of a ferrous 
complex. The ferrous complex immediately takes a molecule of oxygen and forms a ferrous-oxy state  
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(oxy-complex), which has a redox potential of ~0-20mV (Pompon and Coon, 1984). This intermediate 
is the last intermediate in the reaction pathway that can be easily observed and constitutes the first of 
three branch points in the P450 catalytic cycle. It can either unproductively decay to release a 
superoxide ion and form ferric form again, or consume another electron to pursue the productive path. 
Upon this second reduction, the oxy-complex forms a peroxo- anion species, which readily accepts a 
proton through the proton delivery pathway usually formed by an acid-alcohol pair of amino acids in 
the I-helix. This gives rise to hydroperoxo- form. The peroxo- and hydroperoxo- species are collectively 
termed compound 0 (Cpd 0). The hydroperoxo- species constitutes the second branch point between 
the productive and unproductive routes. It can either get protonated at the proximal oxygen and 
unproductively release a molecule of hydrogen peroxide returning to the ferric state, or it can get 
protonated at the distal oxygen to release a molecule of water and form a higher valent ferryl-oxo 
species, also called Compound I (Cpd I). Cpd I is a highly reactive species and is the third branch 
point in the cycle. Cpd I either takes up two electrons and two protons to produce a molecule of water 
and unproductively return to initial ferric state, or abstract a hydrogen molecule from the substrate and 
through an oxygen rebound mechanism (Groves and McClusky, 1976) insert an oxygen atom, forming 
the hydroxylated product before returning to the ferric low spin state.  
The autoxidation and peroxide shunts result in the formation of superoxide ions and hydrogen 
peroxide, which are potentially harmful species and collectively are called reactive oxygen species 
(ROS). The unproductive pathways are collectively termed uncoupling pathways, and the rates at 
which uncoupling pathways occur determine the overall efficiency of the enzyme (Denisov et al., 
2005a; De Montellano, 2015). Coupling efficiency varies in different P450 isozymes, and coupling 
depends on many factors, including substrate structure and orientation, efficiency and rate of proton 




1.3 P450s in hormone biosynthesis 
Hormone biosynthesis in humans is a result of the steroidogenic pathway (Figure 1.2) that begins with 
the side chain cleavage of cholesterol to form pregnenolone (PREG) catalyzed by CYP11A1 in the 
mitochondrial inner membrane of adrenal cortical cells. PREG is transported out of the mitochondria 
to the endoplasmic reticulum where it can be converted to progesterone by a non-P450 3b-
hydroxysteroid dehydrogenase (3b-HSD) enzyme. Both PREG and PROG are substrates for the 
androgenic CYP17A1, producing 17a-hydroxy products (OH-PREG and OH-PROG). These can be 
converted by CYP17A1 to androgens. PROG and OH-PROG can be shunted towards corticosteroid 
production, following hydroxylation at carbon-21 by CYP21A2, with PROG forming deoxy-
corticosterone and OH-PROG giving rise to 11-deoxycortisol. These are then oxygenated by 
CYP11B1 to form corticosterone and the glucocorticoid cortisol, and the former is further acted upon 
by another P450, CYP11B2 to form the mineralocorticoid aldosterone. These enzymes are localized 
to the zona glomerulosa of the adrenal cortex. Mineralocorticoids are essential for maintenance of salt 
and water balance thereby ensuring blood pressure homeostasis. 
It has been known since 1939 that estrogens are a product of androgen precursors (Nathanson et al., 
1939). The androgens androstenedione and testosterone act as substrates for CYP19A1 which 
catalyzes a three-step reaction resulting in the formation of estrogens. The reactions catalyzed by 
CYP17A1 and CYP19A1 in the steroidogenic scheme from PREG and PROG onwards are discussed 
in the following sections. 
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Figure 1.2: Steroidogenic pathway (red arrows depict CYP17A1 catalyzed steps, brown arrows 
represent CYP19A1 mediated reactions; green arrows represent reactions catalyzed by P450; 
open arrows represent reactions catalyzed by non-P450 enzymes). 
(Gregory, 2016) 
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1.3.1. CYP17A1 mediated androgen synthesis: 
CYP17A1 is a bifunctional enzyme sitting at the crossroads of corticoisteroid and androgen synthesis. 
It is expressed primarily in zona fasciculata and zona reticularis of adrenal cortex, Leydig cells of the 
testis and in small quantities in the brain, placenta and kidneys. CYP17A1 acts on PREG and PROG 
substrates and catalyzes the formation of OH-PREG and OH-PROG. Both these products and their 
substrates can be converted to corticosteroids, resulting in the formation of aldosterone, corticosterone 
and cortisol. OH-PREG and OH-PROG are also substrates for a subsequent reaction catalyzed by 
CYP17A1, in which the C17–C20 bond is cleaved to form androgenic products 
dehydroepiandrosterone (DHEA) and androstenedione (AD) respectively. These products can be 
converted to the active androgens- androstenediol and testosterone by 3b-HSD, or to estrogens by 
CYP19A1 according to the requirement in the body.  
Prostate cancer affects millions in the United States each year, and more than 80% of the cases are 
driven by the action of androgens. Targeting disease progression in PC patients is accomplished by 
prevention of androgen synthesis by surgical castration or by blocking the hypothalamic-pituitary-
gonadal (HPG) axis (chemical castration). This is called Androgen Deprivation Therapy (ADT) and is 
achieved by targeting the gonadotropin-releasing hormone (GnRH) receptor which ultimately inhibits 
androgen production in the testes. However, androgen production from adrenals still goes unhindered, 
which requires co-administration of androgen receptor (AR) antagonists. This treatment strategy is 
rarely curative since most patients relapse and advance to castration resistant prostate cancer 
(CRPC). If untreated, CRPC patients die in less than a year. Reports suggesting that CRPC remains 
dependent on AR signaling led to interest in therapeutics targeting the latter, invariably by strategies 
inhibiting CYP17A1 mediated androgen synthesis itself. In December 2012, the FDA approved 
abiraterone acetate (Zytiga® tablets, made by Janssen Biotech, Inc.), which is a type II binding 
inhibitor of CYP17A1 for use in CRPC patients. Abiraterone binds to the heme iron in CYP17A1 active 
site and as such prevents any activity of the enzyme. However, this treatment strategy is far from 
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perfect. In addition to inhibiting lyase reactions, this also results in inhibition of the 17a-hydroxylation 
activity, which is required for glucocorticoid synthesis and ablation of hydroxylation activity results in 
increased production of mineralocorticoids. This causes elevated levels of adrenocorticotrophic 
hormone (ACTH) and manifests as hypertension, hypokalemia and peripheral edema (Auchus, 2001). 
For this reason, treatment with abiraterone requires co-administration of a synthetic corticosteroid, 
prednisone (Stein et al., 2012).  
Current efforts towards better therapeutics for CRPC patients focus on specific targeting of CYP17A1 
lyase activity, without causing any effect on the essential hydroxylation reactions. Considering the 
stark differences between the two activities, a better mechanistic understanding provides hope for 
better therapeutics for CRPC. There is also a need for better anti-androgens for treating androgen 
excess in females suffering from polycystic ovarian syndrome (PCOS). PCOS is one of the most 
common metabolic disorders affecting women of reproductive age and is characterized by 
hyperandrogenism and ovulatory dysfunction, and is associated with metabolic syndrome, type 2 
diabetes, insulin resistance and increased risk for cardiac disease. Current treatment options include 
anti androgen therapy with steroidal AR antagonist Cyproterone acetate combined with progestogens. 
However, this regimen is marred by serious adverse effects of thromboembolism and hepatotoxicity, 
as well as depression. Clearly, a better understanding of androgen synthesis would fulfill the need for 
improved therapeutics for PCOS patients suffering from androgen excess. 
 
1.3.2. Mechanistic questions in CYP17A1 mediated androgen synthesis: 
As mentioned in section 1.2.2 above, all P450 mediated hydroxylation proceeds through a ferryl-oxo 
intermediate called compound I, which abstracts a hydroen before inserting the active oxygen, 
resulting in the formation of a hydroxylated product. On the other hand, the mechanism of the 
CYP17A1 mediated scission of the carbon-carbon linkage has been a subject of intense research but 
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controversial. Akhtar and coworkers have suggested that while the hydroxylation and lyase reactions 
both occur in the same active site of the protein, they involve different iron-oxygen species. While 
hydroxylation proceeds through a ferryl-oxo (Cpd I) intermediate, lyase reaction involves a direct 
involvement of peroxo-anion species (Akhtar et al., 1994). This proposal has received some support 
over the years, but definitive proof had been wanting until 2015, when Gregory and Mak succeeded 
in spectroscopic isolation of an intermediate which was characterized to be the hemiketal intermediate 
formed as a result of peroxo-anion mediated nucleophilic attack on carbonyl-20 of OH-PREG (Mak et 
al., 2015). This was a seminal finding, a result of years of research probing the catalysis of DHEA 
formation from OH-PREG.  
Initial indication of peroxo-anion mediated scheme being the major mechanistic route for this reaction 
came from the observation of inverse kinetic solvent isotope effect (KSIE) in this reaction (Gregory et 
al., 2013b). KSIE is the ratio of product turnover rates in protiated versus deuterated solvents. For 
most P450 catalyzed reactions observed KSIE is in the range 1.5 – 2.5, indicating rate-limiting 
protonation steps on the path to Cpd I formation. The unusual inverse KSIE in OH-PREG lyase 
reaction has been thought to stem from the ablation of proton dependent unproductive pathways 
(peroxide shunt and oxidase shunt) causing a decrease in uncoupling in reactions with deuterated 
components (Figure 1.3). Resonance Raman spectroscopy is an impressive technique for 
investigating even minor changes in the vibrational modes of heme planar ring and more importantly 
in the diatomic ligands bound to the heme iron, information that is very useful for probing the 
mechanistic intermediates in the P450 cycle. Resonance Raman studies with CYP17A1 oxy-complex 
bound to OH-PREG and to OH-PROG showed that owing to different functional groups at 3b position 
in the A ring, the resulting conformation of these substrates near the O-O ligand bound to the iron is 
different, which may translate into major differences in the mechanism of catalysis of these two 
substrates (Gregory et al., 2013a). Moreover, OH-PREG was observed to be positioned such that the 
17a-OH group donates a hydrogen bond to the proximal oxygen of the oxy-complex, whereas in the 
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case of OH-PROG a hydrogen bond was formed with the distal oxygen. This positioning of OH-PREG 
causes the distal oxygen of the oxy-complex to be in a position conducive to perform a nucleophilic 
attack on the carbonyl-20 of the substrate which would result in the formation of an acyl peroxo-iron 
(hemiketal) intermediate. Further indication came from optical spectroscopic investigation of reaction 
intermediates following thermal annealing of cryo-trapped peroxo-anion intermediate bound to OH-
PREG, which strongly suggested that OH-PREG lyase chemistry does not proceed through Cpd I like 
PREG does, but rather through a different intermediate with an absorbance maximum at 405 nm (Mak 
et al., 2015).  
Final proof that peroxo-anion species forms a hemiketal intermediate in OH-PREG chemistry came 
from resonance Raman measurements of thermally annealed cryo-trapped peroxo-anion intermediate 
bound to OH-PREG. While PREG bound peroxo-anion intermediate quickly proceeded to hydroperoxo 
species even at 77 K, with OH-PREG there was no hydroperoxo observed even at 165K. In order to 
follow the peroxo-anion in this case, a 406 nm excitation laser was used, a wavelength closer to the 
absorbance maximum of the new intermediate observed in optical annealing experiments. With this 
laser, a new intermediate was observed, which was H/D exchange independent and exhibited O–O 
vibrational modes similar to acyl-peroxo iron(III) species isolated in some non-heme reactions by Que 
and coworkers (Oloo et al., 2014). Definitive characterization of this intermediate as the proposed 
hemiketal intermediate came from oxygen isotope scrambling experiments, with a mixture of 16O2, 
16O18O and 18O2. Using this gas mixture, it was convincingly shown that both the oxygen atoms in the 
proposed hemiketal intermediate came from an unbroken oxygen molecule. Had this intermediate 
been a result of ferryl-oxo mediated H-abstraction from 17a-OH, there wouldn’t be a 18O–18O 





Figure 1.3: Distinction between CYP17A1 mediated mechanism of hydroxylation and lyase 
reactions highlighting the proton dependent steps. The blue arrows represent hydroxylase 
mechanism starting from peroxo-anion species resulting in the formation of compound I that 
forms the hydroxylated product and requires two protons. The red arrows represent the two 
possible hypotheses for lyase mechanistic pathway. The androgen product can be formed from 
peroxo-anion directly via a proton independent mechanism, or by the conventional compound 
I intermediate. 
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As mentioned above, in contrast to OH-PREG bound oxy-complex, OH-PROG bound oxy-complex 
has a different hydrogen bonding conformation. While the distal oxygen is free to attack the carbonyl-
20 of OH-PREG, in OH-PROG the distal oxygen of the peroxo-anion would be less amenable for a 
similar reaction. This observation might have defining effects on the mechanism of OH-PROG lyase 
reaction, which might proceed through a Cpd I intermediate. Similar studies investigating the active 
intermediate in OH-PROG lyase reaction are lacking with homogeneous membrane bound full length 
human CYP17A1, whether this reaction follows a peroxo-anion mediated mechanism like OH-PREG, 
or if it proceeds through a conventional Cpd I intermediate. 
 
1.3.3. Mechanism of cyt b5 mediated modulation of androgen synthesis: 
Another particularly intriguing aspect of CYP17A1 reactivity is its selective dependence on the 
membrane bound form of cyt b5 for the lyase reaction, whereas hydroxylation reactions remain barely 
affected. Immuno-histochemical studies of the adrenal cortex have shown that cyt b5 is expressed 
along with CYP17A1 in zona reticularis, the site that produces androgens but not corticosteroids, and 
not in zona fasciculata, where only corticosteroids are produced (Dharia et al., 2004; Suzuki et al., 
1992). Additionally, the expression of cyt b5 increases at the onset of adrenarche, correlated with 
increase in androgen production at these sites. The presence of membrane bound form of cyt b5 has 
been known to selectively and significantly enhance the rate of the lyase reaction and is therefore 
important for maintaining normal levels of androgens (Sergeev et al., 2014). Mutations of R347, R358 
and R449, the CYP17A1 surface residues involved in cyt b5 binding results in impairment of lyase 
activity (Lee-Robichaud et al., 1998). Mice models with testicular Leydig cells lacking cyt b5 show 
considerable loss of lyase activity (Sondhi et al., 2016). It is also known that male subjects lacking 
functional cyt b5 present with pseudo hermaphroditism, while high cyt b5 levels in adrenocortical 
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adenomas in Cushing’s syndrome patients correlate with increased androgen synthesis (Sakai et al., 
1994).  
Cytochrome b5 has been known to play a significant role in many P450 mediated reactions, fatty acid 
biosynthesis  and hepatic drug metabolism (Oshino et al., 1971). For instance, Sato and co-workers 
suggested that the binding of cytochrome b5 (cyt b5) to cytochrome P450 elicited a structural change 
in the enzyme which activated product turnover, either by increasing the inherent catalytic rate or by 
inhibiting non-productive auto-oxidative shunt processes (Imai and Sato, 1977). Alternatively, as cyt 
b5 contains a bis-imidazole coordinated heme, direct transfer of electrons from cyt b5 to P450 has been 
proposed (Bonfils et al., 1981; Imai and Sato, 1977). In this role, the relatively high redox potential of 
cyt b5 i.e. ~0 mV versus Normal Hydrogen Electrode (Rodgers and Sligar, 1991) suggests that electron 
transfer to ferric P450 (redox potential ~300 mV vs. NHE) is unfavorable. Hence it was suggested that 
the redox function of cyt b5 involved electron transfer to the ferrous dioxygen intermediate which has 
a redox potential near 0 mV (Lipscomb et al., 1976) thus providing the second electron in the reaction 
chemistry. To differentiate between these two roles, Coon and co-workers reconstituted apo cyt b5 
with manganese protoporphyrin IX (Morgan and Coon, 1984). They found cytochrome P450 reductase 
(CPR) and NADPH could not reduce the manganese substituted cyt b5, whereas iron cyt b5 was rapidly 
reduced. Hence Mn b5 is incapable of any electron transfer to the P450. They concluded that cyt b5 
effects depend on the specific P450 in question, the substrate being examined, and molar ratio of CPR 
to P450. This suggested that their observations could not be explained solely by a simple electron 
transfer role and some effects may also be caused by possible conformational changes caused by cyt 
b5 binding. 
The nature of this CYP17A1–cyt b5 interaction has been controversial (Estrada et al., 2013; Im and 
Waskell, 2011; Sergeev et al., 2014; Zhang et al., 2007). Auchus and coworkers used apo b5 and 
observed that it stimulated the lyase reaction in recombinant yeast, leading these workers to conclude 
that there is no redox role (Auchus et al., 1998). On the other hand, Estabrook and others 
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demonstrated in an in vitro reconstituted system in the presence of lipids that a zinc substituted cyt b5 
did not stimulate the lyase activity of CYP17A1, and that the previous reports of rate enhancement by 
apo b5 are the result of transfer of the heme group from the P450 to apo b5 forming the holoenzyme 
(Guryev et al., 2001). Conceivably, better understanding of this interaction between CYP17A1 and cyt 
b5 is valuable from a therapeutic interest standpoint to specifically target androgen synthesis in 
diseased states.  
Using solution NMR on soluble forms of both proteins and with the help of earlier mutagenesis 
experiments by the Akhtar group and others, Scott and co-workers have identified the cyt b5 putative 
binding site on CYP17A1 surface (Estrada et al., 2013; Lee-Robichaud et al., 2004; Naffin-olivos and 
Auchus, 2006). As is the case with other P450s like CYP2B4, cyt b5 is believed to occupy a binding 
site that is partially overlapping with that of CPR (Zhang et al., 2007). This finding raises interesting 
possibilities. If cyt b5 is just an allosteric modulator, this would entail that when it binds to the CYP17A1 
molecule, the associated conformational changes occur, but for catalysis to move forward, cyt b5 has 
to be displaced by the CPR molecule to perform reduction of the P450. This would require that the 
CYP17A1 somehow ‘remembers’ the cyt b5 modulated conformational changes even after the latter is 
unbound. On the other hand, if cyt b5 acts as an electron partner for the second reduction, after CPR 
has carried out the first reduction, cyt b5 could bind and along with any associated conformational 
changes, reduce the oxy-complex and result in a faster turnover cycle. In chapters 4 and 5, I have 
tried to answer this long-debated question, whether in CYP17A1 mediated lyase chemistry, cyt b5 acts 
as a redox partner, an allosteric effector, or does it carry out a combination of both functions. 
 
1.3.4. CYP19A1 mediated estrogen synthesis and mechanistic questions: 
CYP19A1 (aromatase) enzyme, primarily expressed in ovaries, testes and brain, catalyzes the 
synthesis of estrogens from androgens in a three-step process. During this process, it consumes three 
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molecules each of NADPH and dioxygen per estrogen product molecule. CYP19A1 acts on a total of 
three androgenic substrates: androstenedione, testosterone and 16a-hydroxy-testosterone to produce 
the estrogenic products estrone, 17b-estradiol and estriol, respectively. Inactivating mutations of 
CYP19A1 have been known to result in pseudo-hermaphroditism in females and tall stature and 
delayed skeletal maturation in males (Jones et al., 2007). These symptoms can be reversed by 
estrogen replacement therapy. Mutations resulting in over activation of CYP19A1 are known to cause 
gynecomastia in males and a premature growth spurt but a decreased adult height (Shozu et al., 
2003). Genetic mutations in CYP19A1 affecting estrogen synthesis are very rare. From the clinical 
standpoint, a more significant role of CYP19A1 lies in its involvement in estrogen dependent breast 
cancers in post-menopausal females.  
After menopause occurs, the ovary is no longer the primary location of estrogen synthesis, instead the 
endothelial tissue, smooth muscle cells, skin and adipose tissue including the adipose tissue of breast 
take on this role. The estrogens synthesized here act in an autocrine or paracrine manner. Therefore, 
despite low circulating levels, the concentration of estrogen in the breast tissue of post-menopausal 
patients is several fold-higher than that in pre-menopausal women. Abnormally high estrogen levels 
in the breast can cause over-activation of estrogen receptor, which in turn can result in tumorigenesis. 
Majority of all breast cancers are either estrogen receptor dependent (ER+), or progesterone receptor 
dependent or both. In order to intervene ER+ cancers, ER antagonists such as Tamoxifen have been 
in clinical use for about 4 decades (Willis et al., 1977). Unfortunately, Tamoxifen therapy suffers from 
severe side effects, viz. increased risk for endometrial cancer, thromboembolism and stroke, and 
patients have been seen to relapse even decades after their initial treatment. Another therapeutic 
strategy is to inhibit CYP19A1 using exemestane, anastrozole or letrozole, a class of compounds that 
act as competitive inhibitors of the enzyme by binding irreversibly in the active site. CYP19A1 inhibitors 
have fewer side effects as compared to Tamoxifen therapy, but the patients are still at risk for heart 
disease and osteoporosis. Increased understanding of CYP19A1 molecular mechanism will help guide 
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efforts towards better mechanism based CYP19A1 inhibitors for improving prognosis in ER+ breast 
cancers. 
Each CYP19A1 mediated estrogenic reaction proceeds through three sequential steps as depicted in 
Figure 1.4. Step I involves hydroxylation at the C-19 position, step II is another hydroxylation on C-19 
position, the resulting geminal hydroxy product undergoes dehydration to form a 19-aldehyde. Step III 
comprises scission of C10–C19 bond, resulting in aromatization the A-ring of the steroid substrate and 
loss of C19 as a molecule of formic acid (Akhtar and Skinner, 1968; Akhtar et al., 1993; Braselton et 
al., 1974; Ghosh et al., 2010; Lo et al., 2013; Thompson Jr. and Siiteri, 1974). Similar to CYP17A1, 
the CYP19A1 mediated hydroxylations during the step I and II reactions are generally believed to 
proceed through the conventional high-valent Fe(IV)–O species, Cpd I. However, the mechanism of 
the third step has been controversial.  
There are two hypotheses: a conventional Cpd I intermediate formed as a result of two subsequent 
protonations of peroxo-anion species would abstract 1b-hydrogen from the A-ring of 19-oxo substrate, 
this would initiate aromatization and loss of formic acid side product after C10–C19 bond scission. 
Alternatively, a mechanism involving direct interaction of peroxo-anion with the 19-aldehyde 
functionality has been proposed, in which the peroxo-anion is stabilized by the electrophilic carbonyl-
19 of the substrate (Figure 1.5). It is proposed that 19-oxo substrate binding causes some 
displacement of the Thr 310 of the “acid-alcohol pair”, which in turn results in disruption of proton 
delivery to the peroxo-anion (Graham-lorence et al., 1995). The latter species, now transiently 
stabilized, could carry out a nucleophilic attack on C19, making a peroxide adduct that would undergo 
decomposition resulting in aromatized A-ring of the substrate and release of formic acid side product 




Figure 1.4: CYP19A1 mediated synthesis of estrogen from androgen precursor involves three 
steps: hydroxylation at C-19 (step I); second hydroxylation at C-19 followed by dehydration 
(step II); C10–C19 bond scission (step III). 





Figure 1.4: CYP19A1 mediated synthesis of estrogen from androgen precursor involves three steps: 
hydroxylation at C-19 (step I); second hydroxylation at C-19 followed by dehydration (step II); C10–
C19 bond scission (step III). 
(Khatri et al., 2014a) 
  
mechanism of the third step i. . C10–C19 lyase reaction, in which
two hypotheses have been proposed. In the first postulated mecha-
nism, Cpd 1 is th key reactive species. Aromatization results from
C10–C19 scission of 19-oxo-AD intermediate and subsequent
release of C19 as formic acid, initiated by 1b-hydrogen abstraction
of A-ring of the steroid molecule by Cpd1 [15–17]. Alternatively,
the direct involvement of nucleophilic peroxo-ferric intermediate
with the substrate’s aldehyde functionality resulting in the decom-
position of peroxo hemiacetal intermediate to yield the observed
products has also been proposed [18].
It was shown earlier that in AD-bound CYP19A1 the first interme-
diate that accumulates during the low temperature oxygenation and
subsequent cryoreduction experiment is an unprotonated peroxo-
ferric heme [19]. This suggested that the proton delivery pathway
is more hindered in CYP19A1 in the presence of AD. AD, however,
is the substrate for the hydroxylation step of CYP19A1. 19-oxo-AD,
the substrate for the lyase step of CYP19A1 was not investigated in
this study. The involvement of peroxo-ferric species as the reactive
intermediate has also been suggested in CYP2B4, CYP51 and
CYP17 for C–C cleavage reactions with aldehyde- or ketone-contain-
ing substrates [20–23], and by nitric oxide synthase [24]. Applica-
tion of density functional theory on a minimal CYP19A1 active site
showed an energetic preference for Cpd 1-mediated hydrogen
abstraction from the C1 of 19-aldo AD leading to estrone formation
rather than direct reaction of the peroxo-ferric species with 19-aldo
AD [17]. Importantly, it has been hypothesized that the carbonyl pair
(Thr310-Ala306) of CYP19A1 and the catalytic water molecule could
also be responsible for the H2b abstraction of the 2,3-enolization
processes during the aromatization step, in which the acid-alcohol
pair Asp309 directly participate [7], unlike the indirect role of
Asp251 and Glu244 in hydroxylation by P450cam and P450eryF,
respectively [12]. Recently, Mak et al. characterized the oxy-com-
plexes of AD- and 19-oxo-AD bound CYP19A1 using resonance
Raman (rR) spectroscopy and found no difference in the rR signature
of these two complexes. Their data also suggested the presence of a
H-bonding interaction to the terminal oxygen atom of the Fe–O–O
fragment for both cases, implying the involvement of Cpd 1 in both
reactions [25]. Therefore, the involvement of reactive intermediates
during the final stage of aromatization in the ring A of androgens by
human CYP19A1 remains controversial and lacks an unambiguous
conclusion for the C10–C19 lyase reaction.
Herein, we report investigation of kinetic solvent isotope
effects (KSIEs) on the steady-state turnover of the hydroxylation
(steps I and II) and lyase (step III) reactions by human CYP19A1.
This technique has been shown to be useful in quantitating the
consecutive proton-transfer processes, involved in generating
the high-valent iron-oxo species [6] [26]. Therefore, the effect
of deuterium substitution on the catalytic rates can provide an
important indication of the number and identity of protons
involved in O–O bond heterolysis [13]. As a result, either the
involvement of Cpd 1, which depends on at least two protons
to generate the oxoferryl intermediates ([5a] ? [5b] ? [6]), or
nucleophilic reactivity of a ferric peroxoanion intermediate before
involvement of the proton in O–O bond cleavage could be sug-
gested, as was recently demonstrated for human CYP17A1 [23].
Although several steady-state parameters for the conversion of
AD to estrone have been measured earlier either in human placental
aromatase [6,27–29], recombinant human CYP19A1 expressed in
insects [30,31] or bacteria [32–34], the transient-state kinetic stud-
ies during the conversion of AD to estrone have not been studied
except by the Guengerich group [34]. However, all previous kinetic
studies were performed in detergent solubilized-form and reconsti-
tuted with different stoichiometries of CPR, and the detailed mech-
anism of the lyase reaction was not addressed. In this study, we
employed recombinant human CYP19A1 incorporated in Nanodiscs,
which provides a soluble, homogenous, monodispersed protein with
well controlled stoichiometry during reconstitution with its redox
partner CPR and hence mimics the biological integrity in the mem-
brane [35–37].
2. Materials and methods
2.1. Human CYP19A1 expression, purification and Nanodisc
incorporation
The expression and purification of CYP19A1 and cytochrome
P450 oxidoreductase (CPR) was performed as described [19,38].
The self assembly of CYP19A1 Nanodiscs was performed as
described [37].
2.2. NADPH oxidation
Incorporation of CPR into preformed and purified human
CYP19A1 Nanodiscs was made by direct addition of oligomeric
Fig. 1. Cytochrome P450 catalytic cycle.
Fig. 2. Three-step sequential oxidation of steroid catalyzed by human CYP19A1.
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Figure 1.5: Possible hypotheses for the mechanistic pathway in CYP19A1 mediated estrogen 
synthesis: Peroxo-anion mediated mechanistic pathway (A); Compound I mediated 








Considering the significance of the reactions catalyzed by CYP19A1 for human health, and its 
similarity to CYP17A1 lyase chemistry, I decided to investigate reaction mechanism for CYP19A1 
lyase reaction, whether the key mechanistic intermediate in this reaction is Cpd I or peroxo-anion 
species (Cpd 0). 
 
1.4 Nanodisc technology 
1.4.1. Challenges in the study of membrane proteins: 
Membrane proteins are involved in a variety of essential cellular processes, including signal 
transduction, cell adhesion, metabolite transport, oxidative phosphorylation and ATP synthesis, lipids 
and steroid biosynthesis, and xenobiotic detoxification among other roles. In vitro study of membrane 
proteins has proven to be challenging historically, major reason being the problems caused by working 
outside of the native membrane environment. Most biophysical tools like X-ray crystallography, optical 
spectroscopy, NMR, circular dichroism, ligand binding assays etc. that have been applied widely and 
easily to soluble proteins, fail in the case of membrane bound proteins, on account of their limited 
solubility in aqueous solutions. For ease of purification as well as application to the aforementioned 
biophysical and biochemical techniques, a solubilized state of the protein of interest is desirable. To 
this end, a variety of methods have evolved over the years.  
One strategy to employ these techniques on insoluble membrane proteins is by expressing the protein 
devoid of its membrane anchor region, or by making use of agents that can help solubilize the 
membrane proteins. Clearly, a membrane protein devoid of its membrane anchor does not present as 
a perfect model for the native membrane associating, lipid interacting protein. Moreover, recent 
research has provided mounting evidence that membrane lipids and proteins are not randomly 
distributed, but are found in highly organized domains that are central to the functions of the membrane 
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proteins (Kusumi et al., 2012). However, while the use of detergents helps to maintain the complete 
protein in a solubilized state and often eliminates the undesirable oligomerization, this system is a poor 
mimic of the native lipid environment of the membrane proteins. Furthermore, although some 
membrane proteins retain native like activity in detergent micelles, oftentimes detergents can be 
destabilizing and cause protein denaturation. In the case of P450s, some detergents with structures 
similar to the native substrates can bind in the active site and interfere with ligand binding and turnover 
assays (Annalora et al., 2010; Shah et al., 2016). Another challenge in designing an in vitro system 
that is a good model for the native biology of membrane proteins is the role of phospholipids in the 
activity and downstream functions of the proteins. Examples of such critical protein-lipid interactions 
include interaction of membrane proteins with anionic lipids to activate blood coagulation events, 
signaling processes, cell migration among others (Shaw et al., 2007; Tavoosi and Morrissey, 2014; 
Ye et al., 2016a, 2016b). Furthermore, membrane proteins devoid of a membrane environment may 
display lack of, or altered activities. For this reason, several systems incorporating lipids in contact 
with the membrane proteins have been developed over the years. The simplest of these are mixed 
lipid detergent systems, in which the hydrophobic regions of the membrane proteins are solubilized in 
contact with the hydrophobic chains of lipid solution in detergent. Although an improvement over the 
use of only detergent micelles/bicelles, this system is far from perfect, in that some aggregation events 
may still occur causing decrease in protein activity, making this system less reproducible.  
Phospholipid vesicles (liposomes) have been used to reconstitute membrane proteins in a membrane 
environment. These have proven to be useful for larger protein complexes in which mobility within a 
membrane is essential, and removal of detergents results in better stability of the reconstituted 
proteins. However, the use of liposomes comes with some caveats, the resultant solutions in many 
cases are turbid and viscous, and may result in precipitation over time. Moreover, in the case of integral 
membrane proteins, vesicles only provide access to one side of the protein and it is very difficult to 
control stoichiometric ratios of reacting proteins in this system. Despite these challenges, study of 
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membrane proteins remains an active field owing to their significant roles in a huge number of 
biological processes and being a target of >50% of drugs in the market (Bull and Doig, 2015). 
 
1.4.2. Nanodiscs to incorporate functional membrane protein complexes: 
Nanodiscs provide an exceptional alternative to the aforementioned reconstitution systems for 
membrane proteins. A nanodisc is a discoidal lipid bilayer encircled by a “membrane scaffold protein” 
(MSP) which is a derivative of naturally occurring amphipathic plasma lipoprotein ApoA-I. Since their 
inception in our lab ~15 years ago (Bayburt et al., 2002), nanodiscs have been applied to the studies 
of a variety of membrane proteins including cytochromes P450, G-protein coupled receptors, integrins, 
transporters, bacteriorhodopsin, blood coagulation factors, K-Ras and respiratory proteins (Gingras et 
al., 2013; Gregory et al., 2017; Lamichhane et al., 2015; Luthra et al., 2013; Morrissey et al., 2009; Ye 
et al., 2016a). Membrane scaffold proteins (MSPs) are a-helical proteins, the original sequences of 
which were derived from human ApoA-I lipoprotein. There are a variety of ways in which MSP 
sequences can be manipulated to achieve desired nanodisc size (from 8 nm to 17 nm), or selective 
labeling for fluorescence quenching experiments with removal of background fluorescence (“dark 
MSP”) etc (Grinkova et al., 2010b). In addition to the many benefits of this technology, the procedure 
for their assembly is elegantly simple (Figure 1.6). Purified (or partially purified) membrane protein 
target is incubated with lipids solubilized in the detergent of choice in the presence of desired MSP 
variant, and upon gradual removal of detergent using Biobeads or by dialysis, spontaneous formation 




Figure 1.6: Nanodisc assembly process to incorporate His-tagged CYP17A1 in POPC lipids 
encircled by MSP1D1 followed by complex formation with CPR and cytochrome b5. 
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A plethora of techniques can now be successfully applied to membrane proteins using this technology, 
including but not limited to: resonance Raman, optical absorption spectroscopy, NMR, EPR, 
membrane interaction studies using SPR, AFM, cryo-EM, small angle X-ray scattering, studies of 
membrane association effects on redox potentials of redox active proteins, and investigation of drug-
drug interactions (Bayburt et al., 1998; Das et al., 2007; Denisov et al., 2005b; Efremov et al., 2014; 
Laursen et al., 2014; Mak et al., 2011; Sligar et al., 2007; Zhang et al., 2015). A few unconventional 
ways in which the nanodisc technology has been employed are their use as drug delivery agents, 
vaccines for influenza and personalized cancer immunotherapy, cell free expression of various 
membrane proteins, and optical imaging agents to monitor drug disposition (Bhattacharya et al., 2010; 
Carney et al., 2015; Duivenvoorden et al., 2014; Kuai et al., 2016; Rues et al., 2014). Given the many 
advantages of this system, we used nanodiscs to reconstitute the membrane bound forms of 
CYP17A1, cyt b5, CPR and CYP19A1 in all our experiments. A depiction of an MSP1D1 nanodisc with 




Figure 1.7: A depiction of MSP1D1 nanodisc with incorporated P450-CPR-cytochrome b5 
complex: P450: red, CPR: yellow, cyt b5: orange, MSP1D1: blue helices. 









As described in section 1.3.1, CYP17A1 acts on 17-hydroxy-pregnenolone and 17-hydroxy-
progesterone to form the androgenic products dehydroepiandrosterone (DHEA) and androstenedione 
(AD) respectively. It has been shown recently that in the case of OH-PREG, the reaction proceeds 
through an unconventional hemiketal intermediate formed as a result of nucleophilic attack of peroxo-
anion on the carbonyl-17 (Mak et al., 2015). To investigate whether the alternate lyase reaction that 
involves the synthesis of AD from OH-PROG follows this unique chemistry, or the conventional Cpd I 
reactive intermediate, I measured kinetic solvent isotope effects on steady state product turnover of 
OH-PROG. From Figure 1.1, it is clear that the formation of Cpd I requires at least two protons 
whereas peroxo-anion species is formed independent of protons. The differential requirement of 
protons between the two potential reaction mechanisms is therefore exploited using this technique 
(Gregory et al., 2013b; Vidakovic et al., 1998). 
In order to investigate the reaction mechanism, the various mechanistic intermediates around the P450 
catalytic cycle can be explored by various spectroscopic techniques. By investigating the identity of 
species that appear following formation of peroxo-anion in CYP17A1 bound to OH-PROG, the active 
mechanistic intermediate can be determined. However, intermediates following the oxy-complex in the 
catalytic cycle are extremely short lived and accumulating these highly oxidizing species in amounts 
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sufficient to be amenable to biophysical characterization is not trivial. This obstacle was overcome by 
Symons and coworkers by the development of cryoradiolytic reduction (Kappl et al., 1985; Symons 
and Petersen, 1978), and further refined by other groups to be applied to various techniques including 
EPR, ENDOR, UV-Vis and most recently to resonance Raman spectroscopies (Davydov, 1980; 
Denisov et al., 2008; Makris et al., 2002). This technique involves freeze-trapping the oxy-complex in 
an aqueous solution containing glycerol, followed by irradiation with g-rays at 77 K. This produces free 
electrons and organic radicals, of which only electrons are mobile at this temperature. Hence one 
electron reduction of the Fe–O–O fragment is achieved, giving rise to the peroxo-anion intermediate, 
which remains stable at 77 K while protons are generally immobilized. Upon gradual warming (thermal 
annealing) of the entrapped reactive complex, molecular mobility improves and the next intermediate 
in the pathway can be identified using spectroscopic techniques (Figure 2.1). Using this method, 
considerable accumulation of highly reactive species can be achieved which can be then be applied 
for various mechanistic studies (Denisov et al., 2002). Here, I used UV-Vis spectroscopy to identify 
the species following peroxo-anion intermediate in substrate bound CYP17A1 on the basis of their 
optical signature. 
 
Figure 2.1: Schematic representation of cryo-radiolytic reduction of oxy-ferrous intermediate 
and thermal annealing. Upon  g-irradiation, reduction occurs resulting in the formation of 
peroxo-anion species. When temperature is increased, the next intermediate in the pathway 
is formed.  
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2.2 Materials and methods 
2.2.1 Heterologous expression and purification of recombinant proteins: 
• CYP17A1: 
Full length human CYP17A1 synthetic gene with a His6 tag at the C terminus was incorporated in 
pCWori vector with ampicillin resistance marker and co-transformed with GroEL/ES chaperone system 
(Takara Bio) into E. coli DH5a. Cells were grown in LB-agar (LA) plates with 100 µg/mL ampicillin and 
20 µg/mL chloramphenicol following which transformation was confirmed by 1% agarose gel 
electrophoresis on overnight lysogeny broth (LB) cultures. A fresh LA plate was streaked and grown 
overnight, from which 50mL starter cultures were inoculated. After growing for 8-12 hours at 37 oC, 1 
mL of this culture was used to inoculate 1 L of terrific broth (TB) medium with ampicillin, 
chloramphenicol, thiamine and Bracken’s trace metal solution. The cells were grown at 37 oC until OD 
(600 nm) of 0.4 was attained. At this point, heme precursor d-aminolevulinic acid (d-ALA) was added 
at a final concentration of 1 mM and the culture transferred to 27-29 oC. When OD of 0.7-0.9 was 
reached at 600 nm, 1 mM isopropyl-b-D-1-thiogalactopyroside (IPTG) and 4 mg/mL L-arabinose were 
added as inducers of CYP17A1 and GroEL/ES respectively. The culture was then grown for 48 hours 
after which the cells were pelleted by centrifugation and stored at -80 oC.  
Frozen cell pellet was broken and re-suspended in lysis buffer containing 0.1 M KPi (pH 7.4), 50 mM 
NaCl, 20% v/v glycerol, 50 µM progesterone, 10 mM b-ME, 0.5 mM PMSF, 0.1 mg/mL lysozyme, 0.1 
mg/mL DNase and RNase. This solution was stirred at 4 oC for 30-60 min. Following this, the 
sphaeroplasts obtained were lysed by sonication for 15 min using 0.5 cm tip, 0.6 power and 70% duty 
cycle. The membranes were pelleted by ultracentrifugation at 30,000 rpm for 30 min. at 4 oC and re-
suspended in membrane solubilization buffer containing 0.1 M KPi (pH 7.4), 0.5 M NaCl, 20% v/v 
glycerol, 50 µM progesterone, 10 mM b-ME, 0.5 mM PMSF and 1% Triton X-100. This suspension 
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was stirred at 4 oC for 1-2 hours. Insoluble fraction was pelleted by ultracentrifugation at 30,000 rpm 
for 30 min. The supernatant was applied to charged Ni-NTA resin equilibrated with 0.1 M KPi (pH 7.4), 
0.5 M NaCl, 20% glycerol, 50 µM progesterone, 10 mM b-ME and 1% Triton X-100. The column was 
then washed with buffer A containing 0.05M Tris (pH 7.4), 0.3 M NaCl, 20% v/v glycerol, 50 µM 
progesterone, 10 mM b-ME and 0.02% v/v Emulgen 913 to remove unbound materials. A second 
wash with buffer B containing 20mM MgCl2, 5 mM ATP and 50 mM Imidazole in buffer A was done to 
remove chaperones bound to CYP17A1 and non-specific binding agents. Following this step, 
CYP17A1 was eluted using buffer E containing 300mM imidazole in buffer A and colored fractions 
collected, pooled and dialyzed against 100x volume of buffer D containing 0.1 M KPi, 50 mM NaCl, 
20% v/v glycerol, 50 µM progesterone and 10 mM b-ME (3 exchanges). The dialyzed protein was then 
concentrated using Amicon centrifugal concentrators with 10,000 MWCO and flash frozen before 
being stored at -80 oC. Purity of CYP17A1 was ascertained by the observation of a single band in 
SDS-PAGE and quantification done using UV-Vis spectroscopy with  extinction coefficient of 100 mM-
1cm-1 at 390 nm for PROG bound CYP17A1. 
 
• Cytochrome P450 reductase (CPR): 
Rat full length CPR in pOR262 plasmid obtained from Dr. Todd D. Porter (University of Kentucky, 
Lexington, KY) was expressed and purification was performed as described elsewhere (Shen et al., 
1989). Briefly, after sonication of lysozyme treated cells, membrane fraction was obtained by 
ultracentrifugation and then lysed with 0.2% w/v Triton X-100 in buffer containing to 50 mM Tris (pH 
7.7), 0.5 M NaCl, 0.1 mM DTT, 0.1 mM EDTA and 20% v/v glycerol. Supernatant obtained upon 
ultracentrifugation of this suspension was applied to ADP-agarose column equilibrated with column 
buffer containing 50 mM Tris (pH 7.7), 0.1% w/v Triton X-100, 0.1 mM DTT, 0.1 mM EDTA and 20% 
v/v glycerol. The column was washed with 2.5 mM Adenosine in column buffer and CPR was eluted 
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with 2 mM AMP in column buffer. The eluent was then applied to DEAE-sepharose column and 
washed with DEAE buffer (10 mM Tris pH 7.7, 0.1 mM EDTA, 0.1 mM DTT and 20% v/v glycerol) to 
eliminate Triton X-100 by monitoring OD of eluent at 275 nm. Following complete removal of detergent, 
CPR was eluted by using 0.4 M NaCl in DEAE buffer and yellow colored fractions obtained. Pooled 
fractions were rigorously dialyzed against buffer containing 50 mM KPi (pH 7.4), 20% v/v glycerol and 
0.1 mM DTT. Spectroscopic characterization of purified CPR was done by using Rz ratio (A276 
nm/A456 nm) of 8.7 and concentration was determined using an extinction coefficient of 24.1 mM-1cm-
1 at 456 nm (Porter et al., 1987; Vermilion and Coon, 1978).  
 
• Cytochrome b5 and Membrane scaffold protein (MSP1D1): 
Full length rabbit cytochrome b5 and MSP1D1 were expressed and purified as described (Baas et al., 
2004; Denisov et al., 2004; Mulrooney and Waskell, 2000). 
 
2.2.2 Incorporation of CYP17A1, CPR and cyt b5 in nanodiscs: 
Purified CYP17A1 was incorporated into POPC nanodiscs as reported previously (Gregory et al., 
2013a). For KSIE measurements, four times molar excess excesses of CPR and cyt b5 were used to 
incorporate into the CYP17A1 containing nanodiscs as described (Grinkova et al., 2010a). In order to 
test whether the presence of cyt b5 affects the KSIE for OH-PROG, reactions were carried out both in 
the presence and absence of cyt b5, and then compared to the control reaction set with the 
hydroxylation substrate PROG. For CYP17A1 reactions with OH-PROG as substrate without cyt b5 
present, co-incorporation of redox partners was done using 430.5 pmoles of CYP17A1 in nanodiscs 
incubated with 1722 pmoles of CPR, and in reactions with cyt b5, the 242.8 pmoles of CYP17A1 was 
incubated with 971.2 pmoles each of CPR and cyt b5. For the PROG reactions without cyt b5, 419.4 
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pmoles of CYP17A1 was mixed with 1678 pmoles CPR whereas for reactions with cyt b5, 209 pmoles 
of CYP17A1 was incubated with 838.8 pmoles each of CPR and cyt b5. 
 
2.2.3 Determination of steady state kinetic solvent isotope effect on CYP17A1 catalysis: 
Briefly, 1 mL of CYP17A1 nanodiscs with co-incorporated redox partners in 0.1 M potassium 
phosphate buffer pH/pD 7.4, 50 mM NaCl with 50 µM of corresponding substrate (PROG or OH-
PROG) was taken in a 1 mL stirred quartz cuvette with a path length of 0.4 cm. For deuterated buffers, 
pH value was corrected as pD = pH + 0.40 (Glasoe and Long, 1960). The sample was brought to 37 
oC and reaction was initiated by addition of 600 nmoles NADPH. The reaction was allowed to proceed 
for 15 min while monitoring NADPH consumption using absorbance at 340 nm. At this point, the 
reaction was quenched by adding 8.9 N sulfuric acid, transferred to a 1.5 mL tube, flash frozen in liquid 
nitrogen and stored at -80 oC until analysis. When ready for analysis, 1.5 µL of 10 mM cortexolone 
solution in methanol was added as an internal standard to 800 µL each of the thawed samples. The 
tubes were vortexed for 30 seconds to ensure complete mixing, and extraction of organics was done 
by adding 2 mL dichloromethane. Upon phase separation, lower organic phase was aspirated, 
transferred to a fresh tube, and the solvent dried under a stream of nitrogen. The dried analytes for 
PROG reactions were dissolved in 100 µL methanol and 40 µL of this solution was injected to an 
equilibrated ACE-3 C-18 column (150 x 2.1mm) on HPLC (Waters) and resolved using 45% each of 
methanol and acetonitrile in water as mobile phase at a flow rate of 0.2 ml/min. The product OH-PROG 
was separated on a linear gradient of methanol and acetonitrile from 20% to 80% and detected at 240 
nm. Peak integration was done in Millennium software (Waters). For analysis of AD product from 
reactions starting with OH-PROG substrate, similar extraction procedure was followed, except that the 
product analysis was done using HPLC system (Shimadzu) and peak integration performed using 
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LabSolutions software (Shimadzu). KSIE was calculated as the ratio of product turnover rate in 
protiated buffer to that in deuterated buffer. 
 
2.2.4 Cryo-radiolysis and optical annealing to follow reaction intermediates: 
CYP17A1 nanodiscs sample in 0.1 M potassium phosphate (pH 7.4), 15% v/v glycerol and 400 µM 
substrate (PROG/OH-PROG) was taken and deaerated under a stream of argon. The sample was 
then reduced anaerobically with 1.5-fold excess of sodium dithionite in the presence of 1/40th molar 
amount of methyl viologen as redox mediator. Complete reduction of the samples was ensured by 
monitoring optical spectra using Ocean Optics spectrophotometer placed inside the anaerobic 
chamber. The ferrous samples were then rapidly injected into oxygen saturated solution of 67.5% v/v 
glycerol in 0.1 M KPi pH 7.4 in a methacrylate cuvette kept at 243 K in a dry ice-ethanol bath. The final 
concentration of CYP17A1 was ~30 µM and glycerol was 60% v/v. After mixing for 25 seconds, the 
cuvette was transferred to a second dry ice-ethanol bath maintained at 213 K. The cuvette was then 
transferred to our house-made cryostat (Figure 2.2) maintained at 77 K with liquid nitrogen and fit into 
a Cary 300 spectrophotometer. The visible spectrum was recorded to confirm efficient production of 
the oxy-complex. The cuvette with frozen oxy-complex was stored immersed in liquid nitrogen. This 
temperature is much lower than the glass transition temperature of the solvent, and the samples at 
this temperature remain stable for months. These were then irradiated with 4 Mrad dose of  g-rays in 
a Gammacell 200 60Co source on campus while immersed in liquid nitrogen. Radiolytic fragmentation 
of solvent molecules results in formation of hydrogen atoms, hydroxyl radicals, hydrated electrons, 
CO, aldehydes, ketones, alkanes and alkenes through spur reactions. At 77 K, except the hydrated 
electrons, all the radiolytic products are immobilized. It has been shown previously that the solvated 
electrons produced following 4-6 Mrad doses are optimal for cryolytic reduction of metalloproteins 
(Denisov et al., 2007a).  
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Figure 2.2: Home built cryostat setup fit into Cary 300 spectrophotometer for optical annealing 
experiments. Assembled by Dr. Ilia Denisov as described elsewhere (Denisov et al., 2002). 
 
The samples while still immersed in liquid nitrogen were photo-bleached for ~5 min using a 100 W 
tungsten-halogen lamp. The cuvette was then transferred to cryostat maintained at 77 K and spectra 
were collected with Cary 300 spectrophotometer as the temperature was gradually increased. 
 
2.3 Results 
2.3.1 Effect of H2O vs. D2O on the steady state turnover in CYP17A1 catalysis: 
When PROG was used as the substrate without any cyt b5, the hydroxylated product OH-PROG was 
produced at a rate of 4.63 ± 0.05 min-1 in reactions with protiated buffer, and at a rate of 3.12 ± 0.06 
min-1 in deuterated reactions. When cyt b5 was present in PROG hydroxylation reactions, the product 
OH-PROG was obtained at a rate of 4.01 ± 0.01 min-1 in protiated reactions, and at a rate of 2.40 ± 
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0.01 min-1 in deuterated reactions. These turnover numbers translate to a KSIE of 1.5 in reactions 
without cyt b5, and 1.7 in reactions with cyt b5 (Figure 2.3). This is an expected result, since the 
CYP17A1 mediated hydroxylation of PROG is generally accepted to proceed through the proton 




Figure 2.3: Product turnover rates expressed as nmol product formed per nmol CYP17A1 per 
min. for PROG hydroxylation in H2O and D2O in the absence and presence of cyt b5 (A); Kinetic 
solvent isotope effect calculated as kH/kD in the absence and presence of cyt b5 (B). 
 
On the other hand, for reactions using OH-PROG as starting substrate without cyt b5, the product AD 
was obtained at a rate of 0.11 ± 0.005 min-1 in protiated reactions, and at a rate of 0.12 ± 0.006 min-1 
in deuterated reactions. For reactions with OH-PROG in the presence of cyt b5, product AD was 
obtained at 0.26 ± 0.008 min-1 in protiated reactions, and at a rate of 0.32 ± 0.009 min-1 in deuterated 
reactions. These observations amount to a KSIE of 0.9 in reactions without cyt b5, and 0.8 for reactions 















































Figure 2.4: Product turnover rates expressed as nmol product formed per nmol CYP17A1 per 
min. for OH-PROG lyase in H2O and D2O in the absence and presence of cyt b5 (A); Kinetic 
solvent isotope effect calculated as kH/kD in the absence and presence of cyt b5 (B). 
 
2.3.2 Optical spectroscopic isolation of active intermediate in androstenedione 
synthesis: 
Optical spectra were obtained upon thermal annealing of PROG or OH-PROG bound CYP17A1 
peroxo-anion species from 77 K to 185 K. It is expected that any hydroperoxo- species present would 
have an absorption maximum similar to that of peroxo- species, i.e. ~440 nm (Denisov et al., 2001). 
The results for PROG bound samples are depicted in the form of difference spectra from 160 K to 185 
K with negative absorption band at 439 nm, corresponding to the disappearance of peroxo-anion 
species, with a positive absorption band at 413 nm concomitant with the appearance of a ferric like 
species (Fig. 2.5 left panel). When OH-PROG bound peroxo-anion species was annealed, the 
disappearance of peroxo-anion intermediate was accompanied by appearance of a very distinct 





































Figure 2.5: Difference spectra obtained from 160K to 185K from optical annealing following 
cryolytic reduction of oxy-ferrous intermediate for PROG hydroxylation and OH-PROG lyase 




We observed a normal KSIE value of 1.5 and 1.67 for PROG hydroxylation, consistent with the 
understanding that CYP17A1 mediated hydroxylation reactions proceed through proton dependent 
Cpd I intermediate. From KSIE results with OH-PROG lyase reaction of 0.9 and 0.8, it can be 
reasonably concluded that OH-PROG lyase follows a different chemical mechanism than PROG 
hydroxylation. The mildly inverse value of KSIE in this case, which does not get affected by the 
presence or absence of cyt b5, is suggested to stem from the ablation of proton dependent uncoupling 
pathways viz. peroxide and oxidase shunts in deuterated water reactions as depicted in Figure 1.3. It 
therefore indicates that OH-PROG lyase reaction might also follow peroxo-anion mediated 
mechanism, similar to OH-PREG (Gregory et al., 2013b). The lower magnitude of inverse KSIE in OH-
PROG (0.8) as compared to large inverse KSIE (0.4) in OH-PREG might suggest that OH-PROG lyase 
reaction is mostly uncoupled through autoxidation. 
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Using cryo-reduction and optical annealing, PROG bound CYP17A1 peroxo- intermediate was 
observed to convert to a ferric like species, whereas OH-PROG bound samples showed the 
appearance of a novel intermediate absorbing at 407nm. This intermediate is similar to the 405 nm 
intermediate observed during OH-PREG catalysis (Mak et al., 2015).  
Taken together, the inverse KSIE values and the appearance of a 407nm intermediate upon thermal 
annealing suggest that CYP17A1 catalyzes the lyase reaction of OH-PROG through peroxo-anion 
mediated mechanism, similar to the mechanism described for lyase reaction with OH-PREG (Mak et 
al., 2015).  
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Chapter 3 
Resonance Raman Spectroscopy to Probe the Mechanism of 
CYP17A1 Mediated Androstenedione Synthesis 
 
3.1 Introduction 
Resonance Raman spectroscopy (rR) has emerged as a powerful technique for probing structural 
characteristics of heme-bound enzymes both in their stable resting states and more importantly, in 
their fleeting intermediate states. Raman spectroscopy is a vibrational spectroscopy that uses any 
excitation frequency to observe inelastic scattering from a molecule, the magnitude of the inelastic 
shift informs vibrational, rotational and other low frequency transitions. In the case of colored 
molecules such as heme proteins, the resultant Raman spectrum may be contaminated with strong 
fluorescence, and the useful Raman signal may be too weak in intensity. For this reason, rR 
spectroscopy makes use of carefully chosen excitation frequency which crosses the frequency of the 
excited electronic states and resonates with them. This results in enhancement of the Raman active 
modes in the chromophore, since it absorbs the maximum amount of light, thereby reducing the 
background noise and causing an increase in intensity of observable Raman bands by 102-105 fold 
(Mak, 2016).  
Using the impressive power of rR, a lot of information regarding the heme environment can be 
obtained. The high frequency modes reveal changes in oxidation state, spin state and coordination 
number of the heme iron (Mak and Denisov, 2017). Low frequency markers inform changes in heme 
planarity and the linkages of the porphyrin peripheral groups to the protein cavity by detecting changes 
in propionate and vinyl bending modes. Furthermore, valuable information regarding exogenous 
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ligands bound to the heme iron such as O2, CO, NO, CN- as well as axial linkages with the protein 
(Cys or His) is also obtained (Podstawka et al., 2000). This technique has long been in use for studying 
mechanism of P450s ranging from the simplest CYP101A1 to the complex mammalian P450s 
(Denisov et al., 2008; Mak, 2016; Mak and Denisov, 2017; Mak et al., 2011, 2012, 2014a). It has been 
successfully applied to CYP17A1 reconstituted into nanodiscs, and has provided a remarkable amount 
of information regarding the substrate induced changes in the active site, and the heme oxygen adduct 
formed during substrate catalysis, and characterizing the peroxo- intermediate formed in OH-PREG 
chemistry.  
Using rR spectroscopy on CYP17A1 oxy-ferrous complex with OH-PREG and OH-PROG, Gregory 
and coworkers made a seminal discovery (Gregory et al., 2013a). They found that the orientation of 
the D-ring of the substrates was slightly different near the heme iron, which translated into differential 
hydrogen bonding pattern from the 17a-OH- group to the oxy-complex. When the protein was bound 
to OH-PREG, the hydroxyl group donates a hydrogen bond to the proximal oxygen atom, OP in the 
Fe-O-O fragment, whereas in the case of OH-PROG, this hydrogen bonding interaction is towards the 
distal oxygen atom, OD. This H-bonding pattern is expected to persist in the peroxo- intermediate as 
well, suggesting that the H-bond interaction with the proximal O in the case of OH-PREG would 
prevent the scission of O-O linkage, and allow the distal O to perform nucleophilic attack on the 
carbonyl-20, giving rise to the hemiketal intermediate before decaying into the products DHEA and 
acetic acid. The impact of differential H-bonding on the involvement of a specific mechanistic 
intermediate has been previously observed in the case of nitric oxide synthase (Li et al., 2007). On the 
other hand, the observed H-bonding pattern in OH-PROG bound to oxy-ferrous CYP17A1 could result 
in rapid cleavage of O-O linkage and formation of Cpd I. The observation that OH-PREG is catalyzed 
more efficiently than OH-PROG could be explained by this differential pattern of H-bonding (Flück et 
al., 2003). 
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In the case of OH-PREG, the former scenario was confirmed when thermal annealing of trapped 
peroxo-anion intermediate revealed a novel intermediate that was dramatically different than a Cpd I 
species. Using rR, this intermediate was discovered to be an acyl peroxo- like species and was 
confirmed to be hemiketal intermediate resulting from peroxo-anion by employing scrambled oxygen 
(Mak et al., 2015). As explained above, the differential H bonding pattern to the oxy-complex in OH-
PROG could indicate that this substrate goes through a Cpd I mediated mechanism, since the 
electrophile distal oxygen is not involved in the H bond with C17-OH- moiety. On the other hand, as 
described in section 2.4, steady state KSIE values obtained for the lyase reaction suggest that this 
reaction does not require protons and therefore Cpd I must not be involved. In order to definitively 
answer this question, rR spectroscopy on cryo-radiolytically reduced samples of CYP17A1 in 
nanodiscs bound to PROG or OH-PROG was performed. Samples were prepared in both H2O and 
D2O in order to confidently inform the identity of intermediates as observed, based on whether they 
are H/D senstitive or not. The difference traces between 16O2 and 18O2 were used for analysis, this 
helps to cancel out heme vibrational modes, which would otherwise clutter the raw spectra and hinder 
the characterization of O–O and Fe–O modes. 
This work was performed in collaboration with Dr. Piotr Mak in the laboratory of Prof. James R. Kincaid 
at Marquette University. 
 
3.2 Materials and methods 
3.2.1 CYP17A1 expression, purification and incorporation into nanodiscs: 
The expression, purification and incorporation of CYP17A1 into POPC nanodiscs was performed as 
previously described in section 2.2.  
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3.2.2 Preparation of cryolytically reduced rR samples: 
As described in section 2.2, purified CYP17A1 was assembled in nanodiscs and substrate PROG/OH-
PROG added.  The final composition of the samples was ~40 nmoles CYP17A1:ND in 30% v/v double 
distilled glycerol, 6.25 µM methyl viologen, 450 µM substrate, 0.1 M potassium phosphate pH 7.4, 230 
mM NaCl and 5% v/v methanol. Four such samples were prepared, both protiated and deuterated for 
each substrate. After anaerobic preparation of oxy-complex, cryo-radiolytic reduction was performed 
and the samples kept at 77 K until ready for rR experiments.  
 
3.2.3 rR spectroscopy of substrate bound peroxo-ferric CYP17A1: 
The trapped peroxo- samples at 77 K were excited using a 441.6 nm line by a He-Cd laser (IK Series 
He-Cd laser; Kimmon Koha Co.), and the samples annealed to 190 K were measured with 406.7 nm 
excitation lines from a Kr+ laser (Coherent Innova Sabre Ion Laser). All measurements were done with 
Spex 1269 spectrometer equipped with Spec-10 LN-cooled detector (Princeton Instruments). The slit 
width was 150 μm and 1,200 g/mm grating was used with which the resultant spectral dispersion is 
0.46 cm−1 per pixel. The laser power was maintained at £1mW to prevent photo-dissociation. In order 
to avoid laser-induced heating and protein degradation, the samples were contained in spinning NMR 
tubes (5mm outside diameter, WG-5 ECONOMY; Wilmad). The 180° backscattering geometry was 
used for all measurements and the laser focused onto the sample using a cylindrical lens (Shriver and 
Dunn, 1974). The NMR tubes were positioned into a double-walled quartz low-temperature cell filled 
with liquid nitrogen. All measurements were done at 77 K, and total collection time was around 6 hours 
for the irradiated samples and ~8-9 hours for the annealed samples. Spectra were calibrated with 




3.3.1 rR measurements of irradiated oxy-complex bound to PROG/OH-PROG: 
The irradiated PROG-bound H2O and D2O samples at 77 K were excited using 441.6 nm line and the 
spectra obtained are depicted as 16O-18O difference spectra in Figure 3.1 A, B. A strong positive band 
at 772 cm-1 was observed which showed an expected downshift to 735 cm-1 upon 18O2 substitution. 
The 772 cm-1 mode appears very similar to the hydroperoxo-ferric n(O-O) in the case of PREG bound 
samples (775 cm-1). Significantly, this mode exhibited a 4 cm-1 downshift in D2O samples. Hence, on 
the basis of H/D sensitivity and its frequency, this band was assigned to the n(O-O) stretching mode 
for hydroperoxo-ferric intermediate. The corresponding n(Fe-O) mode was observed at 575 cm-1 and 
was found to be downshifted to 549 cm-1 in 18O2 and by 3 cm-1 in D2O. Clearly, all of the PROG bound 
peroxo-ferric intermediate got protonated to form the hydroperoxo- species even at 77 K, suggesting 
that unlike in PREG bound samples, proton transfer in PROG bound CYP17A1 is more facile (Mak et 
al., 2015). This is an expected result, considering PROG reaction is believed to follow Cpd I 
mechanism, and since the samples had no peroxo- form even at 77 K, they were not annealed further.  
Similar experiment with OH-PROG bound samples exhibited two sets of oxygen sensitive modes as 
shown in Figure 3.1 C, D. A band at 790 cm-1 that shifted to 753 cm-1 in 18O2 did not exhibit H/D 
sensitivity, while the second oxygen sensitive mode at 771 cm-1 shifted to 734 cm-1 in 18O2 and 
downshifted to 768 cm-1 in D2O buffer.  The former was most reasonably assigned to a peroxo- species 
(790 cm-1) and the latter mode was assigned to the hydroperoxo- (771 cm-1) species. The 
corresponding n(Fe-O) modes were observed at 562 cm-1 (peroxo- species with 25 cm-1 sensitivity to 
18O2 and no sensitivity to H/D exchange) and 576 cm-1 (hydroperoxo- species with 26 cm-1 sensitivity 
to 18O2 and 2 cm-1 sensitivity to H/D exchange). These results have a prominent distinction in 
comparison to rR results of OH-PREG bound samples where only the peroxo- intermediate was 
observed at 77 K. 
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Figure 3.1: Resonance Raman results in the form of 16O2-18O2 difference traces of irradiated 
samples of oxy-ferrous CYP17A1 bound to PROG in H2O (A); D2O (B); bound to OH-PROG in 
H2O (C); D2O (D). Excitation line 441.6 nm, total collection time for each rR spectrum used to 
generate the difference trace was 4.0-4.5 h. The subtraction was performed in a way to obtain 
the cleanest difference trace. In some traces, though, there is some positive band at around 
674 cm-1. Its arises most probably form higher intensity of the n7 mode in the 16O2 samples, 
most probably caused by higher amounts of residual ferric form in these samples as compared 
to the 18O2 samples. 
 
Upon closer inspection of the relative positioning of the n(Fe-O) modes, an important observation was 
made. While no peroxo- intermediate was observed for the PROG sample, it is reasonable to expect 
that its n(Fe-O) mode would occur near 554 cm-1 (a frequency close to that observed for the peroxo 
form of the PREG sample). In this way, the observed n(Fe-O) mode at 562 cm-1 of the peroxo- form 
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in OH-PROG sample, indicates an ~8 cm-1 upshift to higher frequency, which is consistent with H-
bonding of the 17-OH fragment to the distal oxygen of the Fe-O-O fragment (Gregory et al., 2013a). 
Therefore, the differential hydrogen bonding pattern observed previously in OH-PROG bound oxy-
complex (upshifted n(Fe-O) in OH-PROG as compared to that in PROG) persists in the peroxo- forms. 
A similar persistence of H-bonding pattern from the oxy form to the peroxo- form was also seen in the 
case of OH-PREG (Mak et al., 2015). 
 
3.3.2 rR measurement of OH-PROG bound peroxo- forms upon thermal annealing: 
The OH-PROG samples were thermally annealed to 165 K and spectra recorded using 441.6 nm 
excitation line. Figure 3.2 shows 16O2–18O2 traces of these samples in H2O and D2O buffers. It was 
observed that a significant part of peroxo- intermediate (790 cm-1) that was observed at 77 K 
disappears at 165 K. In order to explore the fate of the disappeared peroxo- form, 406.7 nm excitation 
line was used on OH-PROG samples. This wavelength was chosen to resonate with the intermediate 
observed during optical annealing experiments which was found to absorb at 407 nm (section 2.3.2).  
The spectra at three different temperatures- 77 K, 165 K and 190 K were recorded using this excitation 
wavelength. OH-PROG samples annealed to 165 K and observed using 406.7 nm laser showed 
appearance of a new species at 785 cm-1 which shifted to 745 cm-1 in 18O2 (Figure 3.3). These modes 
were not seen at 77 K (Figure 3.3A), and did not shift in deuterated buffer at all. These findings 
suggest that this new species is identical to the peroxo-hemiketal intermediate observed previously in 
the case of OH-PREG seen at 791 cm-1. Using oxygen isotope scrambling experiment, it was observed 
that this intermediate originated from an unbroken O-O bond, hence its assignment to hemiketal was 
confirmed (Mak et al., 2015). Intensity of this peroxo-hemiketal species was seen to increase upon 
further increase in temperature to 190 K (Figure 3.4).  
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Figure 3.2: Resonance Raman results depicted as 16O2-18O2 difference traces obtained upon 
annealing the irradiated oxy-ferrous samples bound to OH-PROG from 77 K to 165 K in H2O (A) 
and in D2O (B). Excitation line used 441.6 nm, total collection time for each rR spectrum used 





Figure 3.3: Resonance Raman results depicted as 16O2-18O2 difference traces of irradiated oxy-
ferrous samples bound to OH-PROG at 77 K obtained using 406.7 nm excitation (A); Upon 
annealing the irradiated oxy-ferrous samples bound to OH-PROG from 77 K to 165 K in H2O (B) 





Figure 3.4: Resonance Raman results depicted as 16O2-18O2 difference traces of irradiated oxy-
ferrous samples bound to OH-PROG obtained upon annealing the irradiated oxy-ferrous 
samples bound to OH-PROG to 190 K in H2O (A) and in D2O (B). The new intermediate observed 
at 785 cm-1 is clearly seen to increase in amplitude in comparison to 165 K. 
 
3.4 Conclusions 
From our resonance Raman spectroscopy experiments with PROG bound CYP17A1 irradiated oxy-
complex at 77 K, we observed that all the peroxo- species was converted to hydroperoxo. Similar 
experiment with OH-PROG sample showed both the peroxo- and hydroperoxo- forms. These 
observations are contrary to what was observed in the case of PREG and OH-PREG by Mak and 
coworkers, while PREG exhibited the presence of peroxo- and hydroperoxo- species, in the case of 
OH-PREG protonation of the peroxo- forms did not occur at all. This suggests that due to distinct 
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positioning of the D4 substrates (PROG and OH-PROG), proton transfer is more facile as compared 
to that for D5 substrates (PREG and OH-PREG). This difference in substrate positioning is known to 
stem from the differential hydrogen bonding interactions of the 3b keto/3b hydroxyl in the A ring of the 
substrate with the active site residues (Petrunak et al., 2014). Further annealing of PROG bound 
samples is expected to show increased intensity of the observed hydroperoxo- modes and then 
disappearance when this species forms Cpd I and subsequently, the hydroxylated product. Our rR 
results with PROG are completely consistent with a Cpd I mediated mechanism, as also evidenced by 
KSIE values and optical annealing experiments shown in section 2.3. 
On the other hand, results with OH-PROG samples annealed to 165 K and then to 190 K exhibit a 
more complicated mechanism. While we saw both the peroxo- and hydroperoxo- species at 77 K, as 
the temperature was raised to 165 K, the peroxo- disappeared concomitant with appearance of a new 
species that could be identified using a 406.7 nm excitation laser. Upon further increase in temperature 
to 190 K, the intensity of this species was seen to increase. On the basis of its insensitivity to H/D 
substitution, and its similarity with the new intermediate observed in the case of OH-PREG, this 
intermediate was confidently assigned to be peroxo-hemiketal, derived from nucleophilic attack by the 
peroxo-anion on the carbonyl 20 of OH-PROG substrate (Figure 3.5). Hence, we conclude that OH-
PROG lyase catalysis, like OH-PREG proceeds through the peroxo-anion mediated mechanism. This 
result is entirely in-line with our previously performed KSIE and optical annealing experiments with 






Figure 3.5: Updated P450 reaction cycle with CYP17A1 lyase mechanistic intermediate peroxo-
hemiketal which is formed as a result of nucleophilic attack from peroxo-anion to the carbonyl-




Investigation of the Role of Cytochrome b5 in Androgen Synthesis2 
 
4.1 Introduction 
Cytochrome b5 (cyt b5) is a small hemeprotein which is known to affect the catalysis of a variety of 
P450s. While the primary function of cyt b5 has been long known to be the electron transfer to fatty 
acid desaturase (Oshino et al., 1971), as of now cyt b5 has also been shown to affect the catalysis of 
more than 20 isoforms of P450s, including the drug metabolizing CYP3A4, 2B6, 2C9, 2C19 and 2E1 
(Mokashi et al., 2003; Pompon and Coon, 1984; Yamaori et al., 2003; Yamazaki et al., 1997, 2002). 
In the adrenal cortex, the spacio-temporal regulation of cyt b5 expression gives compelling clues to its 
essential role in steroidogenesis. Cyt b5 is expressed only in the zona reticularis, which is one of the 
primary sites for androgen synthesis, with the its levels steadily increasing with the progression of 
adrenarche (Auchus and Rainey, 2004; Nguyen et al., 2009). That cyt b5 selectively enhances the 
androgenic lyase reaction catalyzed by CYP17A1, was first demonstrated in 1982 (Onoda and Hall, 
1982). Indirect evidence also came from patients suffering from Cushing’s syndrome, who were found 
to produce large amounts of cyt b5 in the adenomas (Sakai et al., 1994). Conversely, patients 
presenting with isolated lyase deficiency were found to have disrupted interactions with cyt b5 (Geller 
et al., 1997, 1999). Given that the only FDA approved CYP17A1 inhibitor suffers from complications 
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due to its blanket inhibition of both the reactions, the interaction of cyt b5 with CYP17A1 presents with 
a very attractive therapeutic potential.  
Various groups have identified the residues key to the CYP17A1-cyt b5 interaction. Mutagenesis 
studies and NMR mapping experiments have confirmed that CYP17A1 surface residues R347, R358, 
R449 and cyt b5 E48 and E49 are essential for a functional interaction (Estrada et al., 2014; Lee-
Robichaud et al., 2004; Naffin-olivos and Auchus, 2006). Solution NMR with soluble forms of CYP17A1 
and cyt b5 has shown conformational changes in F, G and I-helices in CYP17A1, potentially indicating 
an allosteric role for cyt b5. Another important feature of the cyt b5 binding site on CYP17A1 surface is 
that it partially shares the area that binds CPR (Estrada et al., 2014, 2016).  
It has long been debated whether the cyt b5 mediated stimulation of lyase activity is due to its allosteric 
role potentially affecting ligand binding, or if there is an associated electron transfer role owing to the 
presence of a bis- imidazole coordinated heme. In the latter role, the relatively high redox potential of 
cyt b5 (~0 mV versus Normal Hydrogen Electrode) implies that electron transfer to ferric P450 (redox 
potential ~ -300 mV vs. NHE) is strongly unfavorable (Rodgers and Sligar, 1991). Consequently, any 
redox transfer from cyt b5 could only occur to the oxy-ferrous intermediate (redox potential ~0 mV) 
(Lipscomb et al., 1976). Extensive research on the mechanism of cyt b5 mediated modulation of 
CYP2B4 catalysis has shown that in cyt b5 competes with CPR to perform the second electron 
reduction of oxy-complex (Im and Waskell, 2011).  
To identify whether cyt b5 occupies a similar redox effector role in CYP17A1 mediated lyase catalysis, 
I made use of a manganese reconstituted of cyt b5 (Mn b5), which has been shown to be redox inactive 
in the presence of CPR (Morgan and Coon, 1984). Additionally, in order to investigate whether the 
conformational changes associated with cyt b5 binding affect the heme functionality and the active site 
structure of CYP17A1, we performed resonance Raman spectroscopy on ferric CYP17A1 bound to 
lyase substrates, in complex with cyt b5. As discussed in section 3.4 and in (Gregory et al., 2013a), 
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OH-PREG and OH-PROG bind in the CYP17A1 active site with different hydrogen bonding 
conformations to the dioxygen adducts of heme. This is suggested to impact the catalysis of these 
lyase substrates, by differentially making a peroxo-anion mediated nucleophilic attack more feasible 
in OH-PREG vs. OH-PROG. All the aforementioned studies with oxy-ferrous CYP17A1 bound to lyase 
substrates had been performed in the absence of b5. Therefore, we decided to perform similar 
experiments with oxy-ferrous CYP17A1 in complex with cyt b5, in order to probe potential catalytically 
significant effects of this interaction on the orientation of lyase substrates in the active site.  In order 
to prevent spectroscopic interference from the heme moiety of cyt b5, Mn b5 was employed which has 
been shown previously to have an identical structure, but significantly lower spectral overlap in the 
Soret region (Gruenke et al., 1997; Mak et al., 2008). Finally, given the need for the cyt b5 membrane 
anchor in its effects on P450s, Nanodisc reconstituted forms of full length proteins were employed for 
all experiments (Holmans et al., 1994; Sergeev et al., 2014). This system provides an additional 
advantage over other reconstitution systems such as detergent micelles in that the stoichiometric 
ratios of the interacting proteins can be controlled in the native like membrane environment. 
The rR experiments described in this chapter were performed in collaboration with Dr. Yilin Liu in the 
laboratory of Prof. James R. Kincaid at Marquette University.  
 
4.2 Materials and methods 
4.2.1 Protein expression, purification and incorporation into nanodiscs: 
The expression, purification and incorporation of CYP17A1, CPR and cyt b5 into POPC Nanodiscs 
was performed as previously described in section 2.2.  
 
	 55	
4.2.2 Reconstitution of redox inactive manganese substituted cyt b5 (Mn b5): 
Cyt b5 prepared as described in section 2.2.1 was reconstituted with Mn protoporphyrin IX according 
to (Morgan and Coon, 1984), with the following changes: after removal of unbound Mn protoporphyrin 
IX by gel filtration using a G-25 column, the eluate was run through a DEAE-cellulose column which 
was equilibrated with 25 mM Tris acetate (pH 8.0), 1 mM EDTA and 10 mM sodium cholate. A linear 
salt gradient was formed using the equilibration buffer supplemented with 1 M NaCl. Mn b5 fractions 
were characterized based on their Rz ratios, pooled, rigorously dialyzed against 100mM potassium 
phosphate buffer (pH 7.4) and flash frozen in liquid nitrogen before being stored at -80 oC until use. 
Mn b5 was quantified using UV-visible spectroscopy (Figure 4.1) using ε368 = 50 ± 2 mM-1cm-1 and 
ε468= 38 ± 1.5 mM-1cm-1 (Morgan and Coon, 1984). Purity and identity of reconstituted Mn b5 was 
confirmed by denaturing gel electrophoresis and MALDI-mass spectrometry.  
 
 
Figure 4.1: UV-visible spectrum of cytochrome b5 reconstituted with manganese 
protoporphyrin IX. The characteristic peaks at 368 nm, 468 nm and 555 nm with a shoulder at 
588 nm were observed.  
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4.2.3 Measurement of steady state NADPH consumption rates and androgen formation 
rates: 
NADPH oxidation rates and product formation rates were determined with 365 pmoles of CYP17A1 in 
Nanodiscs reconstituted with 4-fold molar excess of CPR, and 4-fold molar excess cyt b5 or Mn b5. 
The solution was brought to 1 mL with 100 mM potassium phosphate (pH 7.4) containing 50 mM NaCl 
and 50 µM OH-PREG or OH-PROG (Sigma) in a stirred quartz cuvette with 0.4 cm path length. The 
solution was equilibrated at 37 oC for 5 min and reaction initiated with 600 nmoles of NADPH. The 
oxidation of NADPH was monitored by change in absorbance at 340 nm for 15 min. At this point, the 
reaction was quenched by adding 50 µL of 8.9 N sulfuric acid. Each reaction solution was transferred 
to a 1.5 mL tube, flash frozen in liquid nitrogen and stored at -80 oC until product analysis. These 
reactions were performed in Cary 300 spectrophotometer fitted with magnetic stirrer and Peltier 
temperature controller.  
Frozen samples were thawed and extraction of analytes was performed as previously documented 
(Gregory et al., 2013b; Khatri et al., 2014b). The analysis for DHEA product from OH-PREG was 
performed by gas chromatography with a DB-17 phenol substituted siloxane column and a flame 
ionization detector on a Hewlett-Packard 6890 gas chromatograph, and the chromatograms were 
processed with Grams/32 AI software. Analysis for AD product from OH-PROG reactions was 
performed using C18 HPLC system (Shimadzu) with a linear gradient of methanol and acetonitrile as 
described in section 2.2.3. 
 
4.2.4 Preparation of Raman samples of Mn b5 complex with ferric and oxy-ferrous 
CYP17A1: 
	 57	
Purified CYP17A1 was assembled in nanodiscs (CYP17A1:ND) and substrate added as described in 
section 2.2.  While all 4 substrates were investigated for ferric samples, only the lyase substrates OH-
PREG and OH-PROG were probed for oxy-ferrous samples. The ferric CYP17A1 samples consisted 
of 85 µM CYP17A1:ND in 15% v/v double distilled glycerol, with 2-fold excess of Mn b5 and 420 µM 
substrate. The final composition of the oxy-ferrous samples was 40 nmoles CYP17A1:ND in complex 
with 2-fold excess of Mn b5 in 30% v/v double distilled glycerol, 6.25 µM methyl viologen, 400 µM OH-
PREG/OH-PROG, 0.1 M potassium phosphate pH7.4, 200 mM NaCl and 5% v/v methanol. 
Preparation of oxy-complex and rR measurements at 77 K were performed as described (Gregory et 
al., 2013a). 
 
4.2.5 rR spectroscopy of ferric and oxy-ferrous CYP17A1 in complex with Mn b5: 
We acquired resonance Raman spectra after adding 2-fold and 4-fold excess of Mn b5. The high 
frequency spectra were acquired using the 406.7 nm excitation line from a Krypton ion laser (Coherent 
Innova Sabre Ion Laser) and changes in the Fe-S stretching mode were investigated using the 356.4 
nm excitation line from the same laser, a wavelength known to selectively enhance this mode 
(Champion et al., 1982). The rR spectra of all samples were measured using a Spex 1269 
spectrometer equipped with a Spec-10 LN liquid nitrogen-cooled detector (Princeton Instruments, NJ). 
The laser power was adjusted to ~10 mW at the sample. All samples were measured in a spinning 
NMR tube to avoid local heating and protein degradation. The spectra were collected using a 180° 
backscattering geometry, with the laser beam being focused as a line image on the sample tube using 
a cylindrical lens. The spectra for oxy-ferrous samples were measured at 77 K, using 413.1 nm 
excitation from Krypton ion laser, which enhances heme modes and internal modes of the Fe-O-O 
adduct. Spectra were calibrated with fenchone (Sigma-Aldrich, WI) and processed with Grams/32 AI 
software (Galactic Industries, Salem, NH).  
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4.3 Results 
4.3.1 Effect of Mn b5 on steady state turnover of CYP17A1 lyase reactions: 
The rates of NADPH oxidation and product formation for OH-PREG in the presence of cyt b5 and Mn 
b5 were compared to the rates in the absence of any added cyt b5. The presence of cyt b5 increased 
the product formation rate ~5 fold, while the addition of Mn b5 did not affect it at all (Figure 4.2 A). 
NADPH consumption rates were close in value in all three cases, 54 ± 1.3 min-1 for cyt b5, 51 ± 1.0 
min-1 for Mn b5 and 46 ± 1.9 min-1 for reactions in the absence of any b5. The efficiency of coupling, 
calculated as the ratio of product formation rate to the rate of NADPH consumption, was seen to be 
maximal in the reactions with cyt b5, while reactions with no b5 and with Mn b5 had similar coupling 
efficiency (Figure 4.2 B). Turnover experiment using OH-PROG as the lyase substrate yielded similar 
results. In the presence of cyt b5, AD formation occurred at a rate of 0.26 ± 0.008 min-1, whereas when 
there was no b5 added, this rate was expectedly slower, 0.11 ± 0.005 min-1. In the presence of the 
redox inactive Mn b5, AD formation occurred at a rate of 0.10 ± 0.013 min-1, very similar to that when 
no b5 was present. Therefore, while cyt b5 enhanced the turnover rate of conversion of OH-PROG to 
AD 2.5 times, Mn b5 had no effect on this reaction at all (Figure 4.2 C).  
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Figure 4.2: Effects of Mn b5 on CYP17A1 mediated catalysis of lyase substrates OH-PREG and 
OH-PROG in comparison to cyt b5. Rates of formation of DHEA product from OH-PREG (A); 
Efficiency of coupling for CYP17A1 mediated conversion of OH-PREG to DHEA (B); Rates of 















































































4.3.2 rR measurements to probe effects of Mn b5 on ferric CYP17A1: 
The presence of Mn b5 in complex with substrate-bound forms of CYP17A1 showed minor changes in 
the spin states (Figure 4.3). As can be seen in trace B, PREG bound CYP17A1 in complex with Mn 
b5 showed an isolated n3 mode at 1488 cm-1 and a small signal for LS population near 1500 cm-1, 
features similar to that for the sample without Mn b5 (trace A). The spin state population was estimated 
using the intensity ratio of IHS/ILS equal to 1.24, a procedure developed by (Mak et al., 2013). The HS 
population of PREG bound CYP17A1 in the presence of a 2-fold excess of Mn b5 was 80%, close to 
the value observed in the absence of Mn b5. In the case of OH-PREG samples, the HS component 
changed from ~57% to ~50% when a 2-fold excess of Mn b5 was present (trace D). Similar results 
were obtained with PROG and OH-PROG bound CYP17A1 in the presence of 2-fold Mn b5 (Figure 
4.4). These values remained the same even in the presence of 4-fold Mn b5, indicating that all of 
CYP17A1 binding sites for cyt b5 had been occupied with 2x excess of the redox partner.  
It is important to note that the frequencies observed for both the low energy and high energy internal 
modes of the heme prosthetic group did not shift relative upon binding to Mn b5, indicating that this 
interaction does not induce significant structural changes of the heme macrocycle or its peripheral 
substituents in the substrate-bound ferric CYP17A1. Importantly, when 356.4 nm excitation was used 
to selectively enhance the n(Fe-S) stretching mode, it was observed that the binding of Mn b5 
increased the strength of Fe-S bond. As depicted in the insets for the low-frequency spectra in Figure 
4.3, the n(Fe-S) stretching modes in samples with Mn b5 appeared at 350 cm-1, as compared to 347 
cm-1 in its absence as shown previously (Mak et al., 2014b). Similar effect on the n(Fe-S) mode was 
observed when 356.7 nm excitation was used on PROG and OH-PROG bound ferric CYP17A1 




Figure 4.3: Low frequency (left panels) and high frequency (right panels) resonance Raman 
traces of PREG (A, B) and OH-PREG (C, D) bound to ferric-CYP17A1 in the absence and 
presence of Mn b5. Excitation wavelength 406.7 nm. Inset bands in the low frequency region 
were acquired with the 356.4 nm excitation line from the same laser, a wavelength known to 
enhance the n(Fe-S) stretching mode (highlighted in color). B and D traces were obtained after 




        
Figure 4.3: Low frequency (left panels) and high frequency (right panels) resonance Raman traces of 
PREG (A, B) and OH-PREG (C, D) bound to ferric-CYP17A1 in the absence and presence of Mn b5. 
Excitation wavelength 406.7 nm. Inset bands in the low frequency region were acquired with the 356.4 
nm excitation line from t  same laser, a wavelength kn wn to enhances the n(Fe-S) stretc ing mode. 





Figure 4.4: Low frequency (left panels) and high frequency (right panels) resonance Raman 
traces of ferric-CYP17A1 bound to PROG in the absence of Mn b5 (A, D); in the presence of 2-
fold Mn b5 (B, E); in the presence of 4-fold Mn b5 (C, F); ferric-CYP17A1 bound to OH-PROG in 
the absence of Mn b5 (G, K); in the presence of 2-fold Mn b5 (H, L); in the presence of 4-fold Mn 
b5 (J, M). Excitation wavelength used 406.7 nm.  
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Figure 4.4: Low frequency (left panels) and high frequency (right panels) resonance Raman traces of 
ferric-CYP17A1 bound to PROG in the absence of Mn b5 (A, D); in the presence of 2-fold Mn b5 (B, 
E); in the presence of 4-fold Mn b5 (C, F); ferric-CYP17A1 bound to OH-PROG in the absence of Mn 
b5 (G, K); in the presence of 2-fold Mn b5 (H, L); in the presence of 4-fold Mn b5 (J, M). Excitation 
wavelength used 406.7 nm.  
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4.3.3 rR measurements to probe effects of Mn b5 on oxy-ferrous CYP17A1:  
Effects of Mn b5 binding on oxy-complex was investigated with both the lyase substrates. When OH-
PREG was bound to oxy-complex and 2-fold Mn b5 added, the key n(16O-16O) and n(Fe-16O) modes 
were observed at 1135 cm-1 and 526 cm-1 (Figure 4.5). The corresponding oxygen isotope bands 
n(18O-18O) and n(Fe-18O) appeared at 1070 cm-1 and 497 cm-1. These modes are identical to previous 
measurements with OH-PREG bound oxy-ferrous CYP17A1 in the absence of Mn b5 (Figure 4.6) 
(Gregory et al., 2013a). Therefore, the presence of Mn b5 did not induce any changes to the 
conformation of OH-PREG near the dioxygen adduct of heme, suggesting that the origin of cyt b5 
mediated enhancement of OH-PREG turnover can be attributed to its electron transfer role alone.  
When similar measurements were done on OH-PROG bound oxy-ferrous samples in complex with 2-
fold Mn b5, n(16O-16O) mode was observed at 1131 cm-1 and n(18O-18O) stretching mode was seen at 
1068 cm-1 (Figure 4.7). Upon expanding this spectral region and comparing it with the spectrum 
acquired with 18O2, we saw a minor conformer of Fe-O-O fragment with the n(16O-16O) mode 
occurring at 1140 cm-1, which is identical to the OH-PROG spectra obtained in the absence of b5 
(Figure 4.8) (Gregory et al., 2013a). Significantly, we observed a new Fe-O-O conformer, with 
n(Fe-16O) mode at 530 cm-1 and corresponding n(Fe-18O) mode at 501 cm-1. This suggests that the 
interaction of OH-PROG bound CYP17A1 with Mn b5 causes partial transformation to a conformer 
with an H-bonding interaction with the proximal oxygen, similar to that of OH-PREG. This is expected 
to make the peroxo-anion mediated nucleophilic mechanism more conducive and hence favor the 




Figure 4.5: Resonance Raman traces of OH-PREG bound oxy-ferrous CYP17A1:ND in presence 
of 2-fold Mn b5 in mid-frequency region. Spectra obtained when 16O2 was used (A); Spectra 
obtained for 18O2 complex (B); difference spectra obtained by subtracting 18O2 trace from 16O2. 




Figure 4.5: Resonance Raman traces of OH-PREG bound oxy-ferrous CYP17A1:ND in presence of 
2-fold Mn b5 in mid-frequency region. Spectra obtained when 16O2 was used (A); Spectra obtained for 
18O2 complex (B); difference spectra obtained by subtracting 18O2 trace from 16O2. All measurements 




Figure 4.6: Resonance Raman spectra depicted as 16O2-18O2 difference traces of PREG (A); and 
OH-PREG (B) bound oxy-ferrous CYP17A1:ND obtained using 413.1 nm excitation line. The 
downshifted n(O-O) and n(Fe-O) modes in OH-PREG samples are consistent with a hydrogen 
bonding interaction from the carbonyl-17 of the substrate to the proximal oxygen atom in the 
oxy-ferrous complex (C). Comparing to Figure 4.5, it is evident that binding of Mn b5 to OH-
PREG bound oxy-complex does not induce any changes in the substrate orientation with 
respect to the dioxy-adduct of the heme. 
(Gregory et al., 2013a) 
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Figure 4.6: Resonance Raman spectra depicted as 16O2-18O2 difference traces of PREG (A); and OH-
PREG (B) bound oxy-ferrous CYP17A1:ND obtained using 413.1 nm excitation line. The downshifted 
n(O-O) and n(Fe-O) modes in OH-PREG samples are consistent with a hydrogen bonding interaction 
from the carbonyl-17 of the substrate to the proximal oxygen atom in the oxy-ferrous complex (C). 
Comparing to Figure 4.5, it is evident that binding of Mn b5 to OH-PREG bound oxy-complex does not 
induce any changes in the substrate orientation with respect to the dioxy-adduct of the heme. 
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Figure 4.7: Resonance Raman traces of OH-PROG bound oxy-ferrous CYP17A1:ND in presence 
of 2-fold Mn b5 in mid-frequency region. Spectra obtained when 16O2 was used (A); Spectra 
obtained for 18O2 complex (B); difference spectra obtained by subtracting 18O2 trace from 16O2. 




Figure 4.7: Resonance Raman traces of OH-PROG bound oxy-ferrous CYP17A1:ND in presence of 
2-fold Mn b5 in mid-frequency region. Spectra obtained when 16O2 was used (A); Spectra obtained for 
18O2 complex (B); difference spectra obtained by subtracting 18O2 trace from 16O2. All measurements 





Figure 4.8: Resonance Raman spectra depicted as 16O2-18O2 difference traces of PROG (A); and 
OH-PROG (B) bound oxy-ferrous CYP17A1:ND obtained using 413.1 nm excitation line. The 
downshifted n(O-O) and upshifted n(Fe-O) modes in OH-PROG samples are consistent with a 
hydrogen bonding interaction from the 17-hydroxyl of the substrate to the distal oxygen atom 
in the oxy-ferrous complex (C). Comparing to Figure 4.7, it is evident that binding of Mn b5 to 
OH-PROG bound oxy-complex induces the transition to a conformer in which the substrate 
orientation is such that the 17-hydroxyl is shifted towards the proximal oxygen atom of the 
oxy-ferrous complex, possibly forming a hydrogen bond.  
(Gregory et al., 2013a) 
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Figure 4.8: Resonance Raman spectra depicted as 16O2-18O2 difference traces of PROG (A); and 
OH-PROG (B) bound oxy-ferrous CYP17A1:ND obtained using 413.1 nm excitation line. The 
downshifted n(O-O) and upshifted n(Fe-O) modes in OH-PROG samples are consistent with a 
hydrogen bonding interaction from the 17-hydroxyl of the substrate to the distal oxygen atom in the 
oxy-ferrous complex (C). Comparing to Figure 4.7, it is evident that binding of Mn b5 to OH-PROG 
bound oxy-complex induces the transition to a conformer in which the substrate orientation is 
consistent with hydrogen bond from the 17-hydroxyl to respect to the proximal oxygen atom of the 
oxy-ferrous complex.  





    
 
Figure 4.8: Resonance Raman spectra depicted as 16O2-18O2 differ nce traces of PROG (A); and 
OH-PROG (B) bound oxy-ferrous CYP17A1:ND obtained using 413.1 nm excitation line. The 
downshifted n(O- ) and upshifted n(Fe-O) modes in OH-PROG samples are consi tent with a
hydrogen bondi g interaction from the 17-hydroxyl of the substrate to th  distal oxygen atom in the 
oxy-ferrous complex (C). Comparing to Figure 4.7, it is vident that bindi g of Mn b5 to OH-PROG 
bound oxy-complex indu es th  transition to a conformer in which the substrate orientation is 
consistent with hydrogen bond from the 17-hydroxyl to respect to the pro i l ygen atom of the 
oxy-ferrous complex.  






In order to investigate whether cyt b5 mediated enhancement of CYP17A1 lyase activity arises from a 
possible electron transfer interaction, I made use of redox inactive form of cyt b5, in which the heme 
was replaced with Mn protoporphyrin IX. Mn b5 failed to stimulate product turnover of either of the two 
lyase substrates, and also showed no effect on coupling efficiency. This indicates that for the 
stimulatory effect of cyt b5 on CYP17A1 androgen synthesis reactions, an electron transfer from the 
former is critical. We then made use of the remarkable ability of rR spectroscopy to probe 
conformational changes near the active site occurring as a result of cyt b5 binding. Experiments with 
ferric form of CYP17A1 in complex with Mn b5 showed minor spin state changes and an increase in 
the bond strength of the Fe-S bond. Collectively, this suggests that while Mn b5 forms a complex with 
substrate CYP17A1, it does not enhance lyase turnover due to its inability to perform electron transfer. 
Upon application of rR on oxy-ferrous forms of CYP17A1 in complex with Mn b5, interesting 
observations were made. When OH-PREG was present in the active site, the observed vibrational 
modes were identical to when no b5 was present. The OH-PREG substrate retained the same 
hydrogen bonding conformation to the dioxygen moiety, which is now known to be favorable for 
peroxo-anion mediated catalysis on the basis of structural studies with X-ray crystallography, rR 
measurements as well as recently by DFT calculations (Bonomo et al., 2017; Gregory et al., 2013a; 
Petrunak et al., 2014). The observation that OH-PREG shows similar H-bonding pattern (Figure 4.7) 
when in complex with cyt b5, lends further support to the hypothesis that in vivo OH-PREG lyase 
reaction proceeds through peroxo-anion mediated mechanism. Additionally, it also suggests that the 
stimulatory effect of cyt b5 on OH-PREG catalysis to DHEA product arises predominantly from its 
electron transfer role, with cyt b5 possibly providing a faster reduction route than CPR. This hypothesis 
was tested and is documented in chapter 5. 
When OH-PROG bound oxy-ferrous CYP17A1 in complex with Mn b5 was probed and compared to 
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spectra obtained in the absence of b5, while the major modes remained unchanged, intriguing new 
Fe-O modes was observed. These correspond to appearance of a new Fe-O-O conformer, which 
only appears when Mn b5 is bound. Based on the 12 cm-1 upshift in values of the new n(Fe-O) modes, 
we believe that this new conformer has an OH-PREG like hydrogen bonding interaction, with the 17-
OH group of the substrate donating an H-bond to the proximal oxygen of the ferrous-dioxygen adduct. 
This is a very exciting observation, in that cyt b5 binding causes subtle conformational changes, 
depending on the identity of the substrate in the active site, and these conformational changes make 
OH-PROG bound CYP17A1 more amenable to the peroxo-anion mediated nucleophilic attack, 












Investigation of Cytochrome b5 as Redox Partner for CYP17A1 
 
5.1 Introduction 
As described in section 4.4, using redox inactive form of cyt b5 we found that for it to exert its 
stimulatory effect on lyase activity, it’s electron transfer ability is critical. Our resonance Raman 
spectroscopy experiments revealed that in the case of OH-PREG bound CYP17A1, aside from minor 
changes to Fe–S mode, binding of cyt b5 does not result in detectable perturbations to the heme 
prosthetic group or to the active site (section 4.4). A recent study by Waskell and coworkers 
demonstrated that cyt b5 improves coupling efficiency in CYP17A1 lyase chemistry (Peng et al., 2016). 
Similar observations were made by us: while cyt b5 improves coupling efficiency in OH-PREG lyase 
reaction, Mn b5 does not, indicating that the effect of cyt b5 on overall coupling stems from its electron 
transfer interaction with the oxy-complex (section 4.4).  
In the CYP17A1 lyase reaction cycle as depicted in figure 3.4, starts when ferric form of the P450 
binds the lyase substrate, partially changing the spin state of the heme from low spin to high spin 
owing to the displacement of aquo- axial ligand. The high spin heme iron then gets reduced by CPR 
to form the ferrous species, which then binds a molecule of atmospheric oxygen and forms the oxy-
ferrous complex. The oxy-ferrous species has been shown to be involved in hydrogen bonding 
interactions with the C17-OH group of both lyase substrates, OH-PREG and OH-PROG, albeit in 
different patterns (Gregory et al., 2013a). The oxy-complex can either autoxidize back to ferric by 
releasing a superoxide ion, or it can get reduced by cyt b5 or by CPR to produce the peroxo-anion 
intermediate. This intermediate is now confirmed to play a key role in the lyase mechanism, by initiating 
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a nucleophilic attack on carbonyl-20 of the lyase substrates, forming the hemiketal intermediate (Mak 
et al., 2015, section 3.4). Steps 1 through 3, which are also shared by P450s catalyzing the canonical 
mono-oxygenation reactions, have been studied in great detail and usually are not the rate determining 
steps of catalysis. Steps 4 and onwards, on the other hand, are each good candidate for being the 
rate limiting step. In the case of CYP101A1 mediated conversion of camphor to 5-exo-
hydroxycamphor, the second electron transfer from the redox partner putidaredoxin to the oxy-ferrous 
CYP101A1 was found to be the rate determining step (Brewer and Peterson, 1988). Considering that 
the stimulatory effect of cyt b5 relies completely on its ability to carry out electron transfer, and that 
based on the redox potentials, the only feasible electron transfer interaction between the two proteins 
is the reduction of the oxy-complex (Lipscomb et al., 1976; Rodgers and Sligar, 1991), we 
hypothesized that the second reduction in the case of lyase substrate OH-PREG may be at least a 
partially the rate limiting step of the reaction, and cyt b5 accelerates this step by providing a faster 
reduction route than CPR.  
It is known that in human androgen synthesis, OH-PREG is the preferred substrate over OH-PROG 
(Flück et al., 2003). Therefore, we decided to investigate the reduction rate of oxy-ferrous CYP17A1 
bound to OH-PREG by cyt b5 and compare with the rate of reduction by CPR. We also determined the 
effects of these redox partners on the autoxidation rate of oxy-ferrous CYP17A1. Because CYP17A1, 
as well as CPR and cyt b5 are incorporated in the membrane, which plays an important role in defining 
their mutual orientation and interactions (Sergeev et al., 2014), we employed Nanodisc technology to 
reconstitute active complexes of these proteins in a native-like membrane environment. Furthermore, 
since the presence of lipids affects the reduction potential of cyt b5 (Kawai et al., 1963), nanodiscs 
present as a perfect model system for determination of rates by which reduction occurs during in vivo 
reactions. In order to compare the rates of oxy-complex reduction with cyt b5 and with CPR, we 
performed rapid mixing experiments of oxygen-saturated buffer with OH-PREG bound ferrous 
CYP17A1 reconstituted in nanodiscs with reduced redox partners. Immediately after mixing, visible 
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spectrum was monitored using photodiode array detector with millisecond resolution over the course 
of 50-200 seconds. To be able to compare the effects of each redox partner on the autoxidation rate 
of substrate bound oxy-ferrous CYP17A1, we also measured the autoxidation rate of oxy-ferrous 
complex of CYP17A1 and oxidation rates of cyt b5 and CPR separately.  
 
5.2 Materials and methods 
5.2.1 Protein expression, purification and incorporation into nanodiscs:  
The expression, purification and incorporation of CYP17A1 into POPC nanodiscs was performed as 
previously described in section 2.2. 
 
5.2.2 Preparation of reduced samples of CYP17A1 and redox partners: 
Purified nanodiscs assembled with CYP17A1 were taken and incorporation of CPR and/or cyt b5 was 
performed by direct addition in 1.1-1.3 fold molar excess of these proteins. The following samples 
were prepared:  
1) Nanodisc reconstituted CYP17A1 (CYP17A1:ND)  
2) Cytochrome P450 reductase   
3) Cytochrome b5  
4) CYP17A1:ND in complex with 1.3 times molar excess CPR  
5) CYP17A1:ND in complex with 1.1 times molar excess cyt b5  
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6) Ternary complex of CYP17A1:ND with cyt b5 and CPR  
After addition of 50 µM OH-PREG to each, the samples were deaerated under a constant stream of 
Argon for 10 minutes. The samples were then transferred to an anaerobic chamber, where they were 
reduced by adding a small excess of sodium dithionite solution at a known concentration (measured 
spectroscopically using e314 = 8 mM-1cm-1) and methyl viologen (1:20 molar ratio to CYP17A1) to 
facilitate reduction. Complete reduction was confirmed by the appearance of single peak for ferrous 
form of CYP17A1 at 410 nm using an Ocean Optics spectrophotometer housed inside the anaerobic 
chamber. 
 
5.2.3 Stopped flow spectroscopy to follow reaction kinetics: 
All experiments were performed on an Applied Photophysics SX.18MV stopped flow 
spectrophotometer using 75 µL mixing volumes with dead time of 1.5 msec. Each anaerobic sample 
prepared in section 5.2.2 above was taken in a gastight syringe. In the second syringe oxygen 
saturated buffer containing the same concentration of OH-PREG was taken. Both these solutions were 
rapidly mixed in 1:1 ratio following which a thousand spectra were collected on a logarithmic time scale 
at 298 K at 0 - 50 sec or 0 - 200 sec time intervals using a diode array detector.  
 
5.2.4 Data Analysis 
The spectra obtained from each sample were arranged in a matrix and the spectrally different 
components and the kinetics of their appearance or disappearance were determined by using singular 
value decomposition (SVD). For autoxidation processes of reduced CYP17A1 and CPR, two distinct 
kinetic processes were identified. In the case of oxidation of reduced cyt b5 only one slow process was 
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observed. For samples containing binary or ternary complexes of proteins, at least three distinct kinetic 
phases were identified and rate constants for all the processes were calculated using single-
exponential or double-exponential fitting subroutines written in MATLAB (Mathworks, US). Because 
three kinetic phases were well separated in time, in most cases they could be analyzed separately, 
i.e. in the time intervals 0 - 0.3 s, 0.5 - 5 s and 5 - 50 or 5 - 200 s. 
 
5.3 Results 
5.3.1 Determination of autoxidation rates of oxy-ferrous CYP17A1, cyt b5 and CPR: 
Using OH-PREG bound reduced CYP17A1, we determined the rate of unproductive decay of OH-
PREG bound CYP17A1 by autoxidation in the absence of any redox partners. A fast process occurring 
at a rate of ~20 s-1 at 298 K was identified, corresponding to formation of oxy-complex. This oxygen 
binding rate was similar to the previously reported for other cytochromes P450 (Denisov et al., 2006, 
2007b). This fast process was followed by a slower process comprising the autoxidative decay of oxy-
complex back to ferric state and simultaneous release of superoxide ion. The rate constant for this 
slow process was determined to be 0.02 s-1 (Figure 5.1A). When only reduced form of cyt b5 was 
rapidly mixed with oxygen, the oxidation process was observed to be very slow, occurring at a rate of 
0.01 s-1 (Figure 5.1B). The oxidation of CPR alone was found to be a multiphasic process, comprising 
of four kinetic processes corresponding to the two-electron oxidations of the FAD and FMN cofactors. 
A fast phase in the initial 500 ms with a rate constant of 6 s-1 was followed by an intermediate phase 
from 0.5 to 5 s with a rate constant of 1.5 s-1. Following this, a slow phase (0.08 s-1) and a very slow 
phase with a decay constant of 0.0006 s-1 were identified (Figure 5.1C). This is in agreement with 




Figure 5.1: Difference spectra depicting autoxidation spectra of OH-PREG bound CYP17A1 (A); 
oxidation of cyt b5 (B); and oxidation of CPR (C) obtained upon rapid mixing of oxygen 
saturated buffer containing OH-PREG with anaerobically reduced proteins. [Insets showing 
exponential fits for the autoxidative process in A, decay of reduced cyt b5 component in B and 
decay of reduced CPR component in C]. 
 
5.3.2 Determination of rates of reduction of oxy-ferrous CYP17A1 by redox partners: 
In the binary complex of CYP17A1 and CPR, three kinetic phases were identified. The fast phase 
attributed to the formation of oxy-complex proceeded with a rate of 18 s-1, and occurred during the first 
500 ms after mixing. This was followed by an intermediate phase with a decay constant of 0.09 s-1 
was followed by a slow phase with a decay constant of 0.01 s-1 (Figure 5.2). Approximately 85% of 
the decay was observed to proceed in the slow phase. Fast phase of CPR oxidation process could 
not be separated in this sample owing to its strong overlap with the Soret region of CYP17A1 spectrum. 
When CYP17A1 was in complex with cyt b5, after the formation of oxy-complex was completed at a 
rate of 24 s-1, an intermediate kinetic phase was observed between 0.5 to 5 s. This was fit to an 
exponential decay constant of 0.9 s-1, followed by a slower phase with a decay constant of 0.044 s-1 
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(Figure 5.3). About 20% of the mixture decayed in the intermediate phase, which constitutes 
disappearance of the oxy-complex and formation of its ferric form and the simultaneous transition of 
cyt b5 from reduced to oxidized form. The spectral signal observed for this process could be well 
represented as 1:1 combination of difference spectra corresponding to autoxidation of oxy-complex in 
CYP17A1 and oxidation of cyt b5.  Both the spectral signal and the stark difference between the decay 
rate of oxy-complex by autoxidation at 0.02 s-1, and the decay to ferric form after reduction by cyt b5 
at a 45-fold faster rate, indicate the direct electron transfer from ferrous b5 to the oxy-complex.  
 
 
Figure 5.2: Difference spectra obtained when anaerobically reduced complex of OH-PREG 
bound CYP17A1 and CPR was rapidly mixed with oxygen saturated buffer containing 
saturating amounts of OH-PREG. Inset: exponential fit for the decay of oxy-complex and the 




Figure 5.3: Difference spectra obtained when anaerobically reduced complex of OH-PREG 
bound CYP17A1 and cyt b5 was rapidly mixed with oxygen saturated buffer containing 
saturating amounts of OH-PREG. Inset: exponential fit for the decay of oxy-complex and the 
reduced cyt b5 component. 
 
Scott and colleagues have used solution NMR to map to the binding sites for CPR and cyt b5, and 
determined that both the redox partners occupy partially overlapping binding sites on CYP17A1 
surface (Estrada et al., 2013). In light of this information, we wanted to determine how the reduction 
rates are affected in a situation where CYP17A1 has access to both the redox partners. In the sample 
with ternary complex of CYP17A1 with CPR and cyt b5 in a nanodisc, both the redox partners are 
available for carrying out reduction of the oxy-ferrous enzyme. In this case, four kinetic processes were 
identified. Formation of oxy-complex was completed in the first 500 ms. From 500 ms to 5 s, two 
intermediate phases were observed: first with a decay constant of 1.3 s-1 and a second intermediate 
	 78	
phase occurring at a rate of 0.2 s-1. A final slow phase with a decay constant of 0.025 s-1 was seen 
from 5 s to 200 s (Figure 5.4). Comparing the kinetics observed in the binary and ternary complexes, 
the rates of disappearance of CYP17A1 oxy-complex in a ternary complex are more comparable to 
that in CYP17A1-cyt b5 complex (1.3 and 0.9 s-1). On the other hand, the decay rate in CYP17A1-CPR 
complex was determined to be at least 10-fold slower than that in the CYP17A1-cyt b5 complex. All 
the determined values of rate constants for their respective kinetic processes for each sample are 
summarized in Table 5.1. 
 
 
Figure 5.4: Difference spectra obtained when anaerobically reduced complex of OH-PREG 
bound CYP17A1 with cyt b5 and CPR was rapidly mixed with oxygen saturated buffer 
containing saturating amounts of OH-PREG. Inset: exponential fit for the decay of oxy-complex 




Table 5.1: Rate constants of all the isolated kinetic processes obtained when anaerobically 
reduced samples were rapidly mixed with oxygen saturated buffer in a stopped flow setup.  
 
5.4 Conclusions 
We observed that oxygen binding to ferrous CYP17A1 saturated with OH-PREG is fast, occurring 
within the first 500 ms and remained unaffected by the presence of CPR or cyt b5. When the decay of 
the oxy-complex was compared, an intermediate phase appeared when cyt b5 was reconstituted with 
CYP17A1 in nanodiscs. This kinetic process with the rate 0.9 s-1 at 298 K is assigned to the electron 
transfer from reduced cyt b5 to the oxy-complex in CYP17A1, resulting in formation of oxidized cyt b5 
and rapid formation of ferric form of CYP17A1. This assignment is based on the clear spectral signal 
corresponding to the linear combination of two processes. It should be noted that this process is 
significantly faster than the second electron transfer from CPR to the oxy-complex in CYP17A1, which 
occured at a rate of 0.09 s-1. Clearly, the rate of reduction of oxy-ferrous CYP17A1 by cyt b5 is 10 
times faster than that by CPR.  
A significant observation was made when both redox partners were present with CYP17A1 in 
nanodiscs. The faster kinetic process with cyt b5 spectral contribution was clearly observed, indicating 
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more favorable interaction of cyt b5 with CYP17A1, even in the presence of CPR. This preference of 
cyt b5 as a redox partner at the second electron transfer step suggests the similar mechanism of the 
NADPH supported catalytic cycling in CYP17A1, where CPR displaces itself from the P450 after 
carrying out the first electron transfer, and gets replaced by reduced cyt b5, which serves as a faster 
second electron donor. In this bound state, cyt b5 may also play the role of an allosteric effector, 
modulating subsequent catalytically important events, such as altering the active site orientation of the 
bound substrate to a more productive conformation as evidenced by our rR experiments with OH-
PROG (section 4.4), or modulating the decay of hemiketal intermediate towards faster release of 
product.  
In conclusion, we measured oxygen binding and oxidation rates of OH-PREG bound, reduced 
CYP17A1, cyt b5 and CPR in nanodiscs by oxygen using stopped flow spectroscopy. Cyt b5 was 
observed to reduce oxy-ferrous CYP17A1 much faster than CPR, and indicated to be the predominant 
redox partner in a ternary complex, where both cyt b5 and CPR were reconstituted with CYP17A1. 
The finding that cyt b5 is the predominant second electron donor in CYP17A1 lyase catalysis accounts 
for our and others’ previous observation that presence of cyt b5 improves coupling efficiency. This also 
agrees with the potential role of cyt b5 as an allosteric modulator for steps of catalysis subsequent to 
the second reduction. These steps are expected to be very fast, and may be occurring before cyt b5 











Considering the unusual solvent isotope effects and reaction chemistry in the lyase reactions leading 
to androgen synthesis, we set out to determine whether the similar lyase step in estrogen synthesis 
follows an identical mechanistic path. As explained in chapter 2, in order to distinguish compound I 
mediated mechanism from a peroxo-anion mediated mechanism, the proton dependence of the former 
can be utilized. We compared kinetic solvent isotope effects (KSIEs) on the steady-state turnover of 
the hydroxylation reactions (steps I and II) and lyase (step III) reaction by human CYP19A1. The 
involvement of Cpd I, which depends on two protons to generate the oxo-ferryl intermediates, or 
nucleophilic reactivity of a ferric peroxoanion intermediate before involvement of the proton in O–O 
bond cleavage could be probed by this technique. 
Although several steady-state parameters for the conversion of AD to estrone have been measured 
earlier either in human placental aromatase (Hagerman, 1987; Kellis and Vickery, 1987; Tan and Muto, 
1986; Thompson Jr. and Siiteri, 1974), recombinant human CYP19A1 expressed in insects (Amarneh 
																																																						
Reproduced in part with permission from  
Khatri, Y., Luthra, A., Duggal, R., and Sligar, S.G. Kinetic solvent isotope effect in steady-state turnover by CYP19A1 
suggests involvement of Compound 1 for both hydroxylation and aromatization steps. FEBS Letters (2014) 588, 3117–
3122. Copyright 2014 John Wiley and Sons. The published version may be found online at 
https://dx.doi.org/10.1016/j.febslet.2014.06.050. 
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and Simpson, 1995; Gartner et al., 2001) or bacteria (Kagawa et al., 2003, 2004; Sohl and Guengerich, 
2010), the transient-state kinetic studies during the conversion of AD to estrone have not been studied 
except by the Guengerich group (Sohl and Guengerich, 2010). However, all previous kinetic studies 
were performed in detergent solubilized form and reconstituted with different stoichiometries of CPR, 
and the detailed mechanism of the lyase reaction was not addressed. In this study, we employed 
recombinant human CYP19A1 incorporated in nanodiscs, which provides a soluble, homogenous, 
monodispersed protein with well controlled stoichiometry during reconstitution with its redox partner 
CPR and hence mimics the biological integrity in the membrane (Denisov and Sligar, 2011; Luthra et 
al., 2013; Schuler et al., 2013).  
 
6.2 Materials and methods 
6.2.1 Expression and purification of human CYP19A1 and rat CPR: 
The expression and purification of CYP19A1 was performed as described (Gantt et al., 2009). CPR 
expression and purification protocol has been described earlier in chapter 2.  
 
6.2.2 Incorporation of CYP19A1-CPR functional complex in nanodiscs: 
The reconstitution of purified CYP19A1 in nanodiscs was performed as described (Luthra et al., 2013). 
Incorporation of CPR into purified human CYP19A1 nanodiscs was done by direct addition of 
oligomeric CPR at 1:4 molar ratio (200 pmol CYP19A1/800 pmol CPR (Grinkova et al., 2010a). 
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6.2.3 Determination of steady state kinetic solvent isotope effects on CYP19A1 
catalysis: 
1 mL of CYP19A1 and CPR solution in 100 mM potassium phosphate buffer, pH 7.4, containing 50 
mM NaCl and 50 µM substrate (AD, 19-OH-AD, or 19-oxo-AD) was brought to 37 °C in a stirred quartz 
cuvette, path length of 0.4 cm. The sample was incubated for 3 min and the reaction initiated with 300 
µM of NADPH. The NADPH oxidation was monitored by recording the absorbance at 340 nm for 10 
min. The reaction was stopped by adding 50 µl of 8.9 N sulfuric acid to bring the pH below 4.0. The 
sample was removed from the cuvette, flash frozen in liquid nitrogen, and stored at -80 °C until product 
analysis. The optical measurements were performed using Hitachi U-3300 spectrophotometer with a 
temperature controller and built-in magnetic stirrer. The rate of NADPH oxidation was determined from 
the slope of absorption at 340 nm during the first three minutes using an extinction coefficient of 6.22 
cm-1mM-1.  
The conversion of AD, 19-OH and 19-oxo-AD to estrone was analyzed by HPLC (Waters). Briefly, 1 
µL of 18 mM progesterone solution in methanol was added to 1 mL each of the reaction sample, as 
an internal standard, and vortexed for 30 sec. 2 mL of chloroform was added to each aliquot and 
vortexed for 30 seconds. The organic phase was removed and dried under the stream of nitrogen. 
The dried sample was dissolved in 100 µL of methanol and 30 µL was injected onto C18 HPLC (150 
x 2.1 mm) ACE-111-1502 with the mobile phase of 45% each of methanol and acetonitrile in water 
and a flow rate of 0.2 ml/min. The 19-hydroxylated and 19-oxo product of AD was separated in the 
linear gradient of methanol and acetonitrile from 20% to 80% in 30 min, and detected at 240 nm. The 
formation of estrogen was detected at 280 nm. Peak integration was performed with GRAM/32 




6.3.1 Steady-state turnover by CYP19A1 in protiated and deuterated solvent systems:  
CYP19A1 and CPR self-assembled in nanodiscs was used to quantitate product formation and 
NADPH oxidation rates in the presence of saturating concentrations of AD and 19-OH-AD for 
hydroxylation and 19-oxo-AD for the lyase reaction at 37 °C and pH/pD 7.4. Deuterated samples were 
prepared by exhaustive exchange of the proteins in corresponding D2O buffers. In order to determine 
the reaction time for the substrates AD, 19-OH-AD and 19-oxo-AD, time-dependent substrate 
conversion was performed and the 10 min incubation time was chosen for the catalytic activity, during 
which the catalytic activity was in linear phase (Figure 6.1). Using AD as the starting substrate, 19-
OH-AD and 19-oxo-AD were obtained in the reaction mixture under steady state conditions. Similarly, 
when 19-OH-AD was used as the starting substrate, 19-oxo-AD and estrone were formed. Starting 
with AD, 19-OH-AD and 19-oxo-AD were obtained with the individual rates of 1.63 ± 0.04 min-1 and 
4.06 ± 0.30 min-1 respectively, (total rate of 5.70 ± 0.34 min-1) when the reaction was carried out in a 
protiated buffer system. Rates of formation of both these products showed substantial slowing upon 
H/D substitution, yielding a KSIE for the step I hydroxylation reaction of kH/kD = 2.7. In both the cases, 
the rate of second product formation was almost 2.5 times faster, suggesting a distributive nature of 
the enzyme. It is noteworthy that both the rates of formation of individual products (0.62 ± 0.07 min-1 
and 1.52 ± 0.15 min-1 for 19-OH-AD and 19-oxo-AD, respectively) as well as total product (2.14 ± 0.22 
min-1), displayed an isotope effect of 2.6 (Figure 6.2).  
The observed KSIE ratios are very similar to reports for hydroxylation reactions catalyzed by other 
P450s (Batabyal et al., 2013; Liu and Ortiz de Montellano, 2000; Vidakovic et al., 1998). This therefore 
confirms that the first two steps of CYP19A1 catalysis i.e. AD to 19-OH-AD and 19-OH-AD to 19-oxo-
AD are classical P450 hydroxylation reactions and involve the classical Cpd I intermediate. For the 
lyase substrate 19-oxo-AD, the rate of estrone formation was 2.5 times slower in D2O (i.e. 7.1 ± 0.8 
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min-1 in H2O versus 2.8 ± 0.8 min-1 in D2O) (Figure 6.2). This corresponds to the KSIE of kH/kD = 2.53, 
similar to that seen when AD was used as the starting substrate. This suggests the involvement of 
same reactive intermediate Cpd I during lyase catalysis as well, in contrast to what we observed in the 
case of lyase reaction mediated by CYP17A1.  
 
 
Figure 6.1: Product formation rates as a function of reaction time for AD to 19-(OH)-AD and 19-
oxo-AD (A); 19-OH-AD to 19-oxo-AD and estrone (B); 19-oxo-AD to estrone (C). Based on these 
results, reaction time of 10 min was used for subsequent experiments. 
 
CPR at 1:4 CYP19A1 (200 pmol)/CPR (800 pmol) molar ratio, as
described [39]. Briefly, 1 ml of CYP19A1 and CPR solution in
100 mM potassium phosphate buffer, pH 7.4, containing 50 mM
NaCl and 50 lM substrate (AD, 19-OH-AD, or 19-Oxo-AD) was
brought to 37 !C in a stirred quartz cuvette, path length of
0.4 cm. The sample was incubated for 3 min and the reaction was
initiated by addition of 300 lM of NADPH. The consumption of
NADPH was monitored by recording the absorbance at 340 nm
for 10 min. The reaction was stopped by adding 50 ll of 9 M sulfu-
ric acid to bring the pH below 4.0. The sample was removed from
the cuvette, flash frozen in liquid nitrogen, and stored at !80 !C
until product analysis. The optical measurements were performed
on Hitachi U-3300 spectrophotometer supplied with temperature
controller and built-in magnetic stirrer. The rate of NADPH oxida-
tion was determined from the slope of absorption at 340 nm dur-
ing the first three minutes using an extinction coefficient of
6.22 cm!1mM!1. A ratio of 1:4 of P450:CPR was chosen based on
previously established optimal ratio of reductase to P450 for
in vitro turnover experiments using the Nanodisc system [39]. In
this approach the reductase, in a dynamic equilibrium with reduc-
tase molecules in solution, inserts into the P450 containing Nano-
disc through its membrane anchoring tail thereby allowing the
formation of an efficient electron transfer complex.
2.3. Catalytic turnover
The conversion of AD, 19-OH and 19-oxo-AD to estrone was
analyzed by HPLC (Waters). Briefly, 1 ll of 18 mM progesterone
solution in methanol was added to 1 ml each of the reaction sam-
ple, as an internal standard, and vortexed for 30 s. 2 ml of chloro-
form was added to each aliquots and vortexed for 30 s. The
organic phase was removed and dried under the stream of nitro-
gen. The dried sample was dissolved in 100 l of methanol and 30
l was injected onto C18-HPLC column, using a 150 " 2.1 mm,
3 lm (ACE-111-1502) with the mobile phase of 45% each of meth-
anol and acetonitrile in water and a flow rate of 0.2 ml/min. The
19-hydroxylated and 19-Oxo product of AD was separated in the
linear gradient of methanol and acetonitrile from 20% to 80% in
30 min, and detected at 240 nm. The formation of estrogen was
detected at 280 nm. Peak integration was performed with GRAM/
32 software (Thermo Fischer Scientific).
3. Results and discussion
3.1. Steady-state kinetic turnover by CYP19A1 in protiated and
deuterated solvent systems
CYP19A1 and CPR self-assembled in Nanodiscs was used to
quantitate product formation and NADPH oxidation rates in the
presence of saturating concentrations of AD and 19-OH-AD for
hydroxylation and 19-oxo-AD for the lyase reaction at 37 !C and
pH/pD 7.4. Deuterated samples were prepared by exhaustive
exchange of the proteins in corresponding D2O buffers.
In order to determine the reaction time for the substrates AD,
19-OH-AD and 19-oxo-AD, firstly time-dependent substrate con-
version was performed and the 10 min incubation time was chosen
for the catalytic activity, during which the catalytic activity was in
linear phase (Fig. 3).
Using AD as the starting substrate, 19-OH-AD and 19-oxo-AD
were detected in the reaction mixture under steady state
conditions. Similarly, 19-oxo-AD and estrone were obtained
when 19-OH-AD was used as the starting substrate for turnover
experiments. Starting with AD, 19-OH-AD and 19-oxo-AD
were obtained with the individual rates of 1.63 ± 0.04 min!1 and
4.06 ± 0.30 min!1, respectively, (total rate of 5.70 ± 0.34 min!1)
when the reaction was carried out in a protiated buffer system.
Rates of formation of both these products showed substantial
slowing upon H/D substitution, yielding a KSIE for the step-I
hydroxylation reaction of kH/kD = 2.7. In both the cases, the rate
of second product formation was almost 2.5 times faster, suggest-
ing a distributive nature of the enzyme. It is noteworthy that both
the rates of formation of individual products (0.62 ± 0.07 min!1
and 1.52 ± 0.15 min!1 for 19-OH-AD and 19-oxo-AD, respectively)
as well as total product (2.14 ± 0.22 min!1), displayed an isotope
effect of P2.6 (Fig. 4A).
These KSIE data are very similar to the reported values for other
well studied P450 systems catalyzing hydroxylation chemistry
[13,40,41]. This was expected since the first two steps of CYP19A1
catalysis i.e. AD to 19-OH-AD and 19-OH-AD to 19-oxo-AD are
standard P450 hydroxylations and are thought to go through the
classical Cpd 1 mediated H-rebound mechanism [42].
When 19-oxo-AD was used as the C10–C19 lyase substrate, the
rate of estrone formation was 2.5 times slower in D2O (i.e.
7.1 ± 0.8 min!1 in H2O versus 2.8 ± 0.8 min!1 in D2O) (Fig. 4C). This
corresponds to the KSIE of kH/kD = 2.53, similar to that seen when
AD was used as the starting substrate. This suggests the involve-
ment of same reactive intermediate Cpd 1 during catalysis. In con-
trast, the involvement of unprotonated peroxo-ferric intermediate
in the catalysis of C17–C20 lyase step by CYP17A1 resulted in a
large inverse solvent isotope effect kH/kD = 0.4 arising from compe-
tition between catalysis hrough a proton-independent intermedi-
ate, viz. the peroxo anion, and uncoupling via proton-dependent
uncoupling pathway(s), viz. the peroxide and the oxidase shunt
[23].
The conversion of 19-OH-AD to its products by CYP19A1 is unu-
sual. Use of 19-OH-AD, substrate for the second hydroxylation
step, as the starting substrate also yielded two products. In H2O,
19-oxo-AD and estrone were obtained at a rate of 2.3 ± 0.2 min!1
and 1.8 ± 0.3 min!1 respectively giving a total rate of 4.1 ±
0.5 min!1. The second hydroxylation step of CYP19A1 also showed
the same distributive nature of the enzyme and gave two products.
However, the rate of second product formation was slower in this
Fig. 3. Time dependent total conversion of AD (A), 19-OH-AD (B) and 19-oxo-AD (C) by CYP19A1.
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Figure 6.2: Product formation rates for CYP19A1 mediated catalysis highlighting kinetic 
solvent isotope effects on conversion of AD to 19-OH-AD and 19-oxo-AD (A); 19-OH-AD to 19-
oxo-AD and estrone (B); 19-oxo-AD to estrone (C). Black bars represent turnover in protiated 
buffer system, white bars represent turnover in deuterated buffer system. 
The conversion of 19-OH-AD to its products by CYP19A1 is unusual. In H2O, 19-oxo-AD and estrone 
were obtained at a rate of 2.3 ± 0.2 min-1 and 1.8 ± 0.3 min-1 respectively with a total rate of 4.1 ± 0.5 
min-1. The second hydroxylation step of CYP19A1 also showed the same distributive nature of the 
enzyme and gave two products. However, the rate of second product formation was slower in this 
case. The rates of 19-oxo-AD and estrone decreased to 2.39 ± 0.14 min-1 and 0.91 ± 0.09 min-1, 
respectively (the total of 3.30 ± 0.23 min-1) in D2O, which gave an overall KSIE of kH/kD = 1.2 (Figure 
6.2). Formation of estrone showed a KSIE of 2.0 (1.8 min-1 in H2O versus 0.91 min-1 in D2O). However, 
the formation of 19-oxo-AD showed virtually no solvent isotope effect bringing the net KSIE of product 
formation down to 1.2. Conversion of 19-OH-AD to 19-oxo-AD goes through a hydroxylation at the 
C19 to produce a gem-diol that then undergoes dehydration to yield the 19-oxo-AD intermediate 
(Figure 6.3). It is plausible that the rate of dehydration of the gem-diol intermediate is partially rate 
case. The rates of 19-ox -AD and estrone d creased to
2.39 ± 0.14 min!1 and 0.91 ± 0.09 min!1, respectively (the total of
3.30 ± 0.23 min!1) in D2O, which gave an overall KSIE of
kH/kD = 1.2 (Fig. 4B). Formation of estrone showed a KSIE of 2
(1.8 min!1 in H2O versus 0.91 min!1 in D2O). However, the forma-
tion of 19-oxo-AD showed no solvent isotope effect bringing the
net KSIE of product formation down to 1.2. Conversion of 19-OH-
AD to 19-oxo-AD goes through a hydroxylation at the C19 to
produce a gem-diol that then undergoes dehydration to yield the
19-oxo-AD intermediate (Fig. 5). It is plausible that the rate of
dehydration of the gem-diol intermediate is partially rate limiting
resulting in a diminished KSIE for 19-oxo-AD formation and giving
rise to a smaller observed KSIE with respect to total product for
step II as compared to steps I and III of CYP19A1 catalysis. It is
noteworthy that the formation of estrone from 19-OH-AD shows
a KSIE >2, which is consistent with other data. Table 1 summarizes
the individual and total product formation rates using AD, 19-OH-
AD and 19-oxo-AD as starting substrates in protiated and deuter-
ated solvents.
3.2. NADPH oxidation rates
The overall rate of NADPH oxidation in the presence of various
substrates of CYP19A1 was also studied. The total rates of conver-
sion of AD and 19-OH in H2O are 37 ± 4.5 min!1 and 37 ± 4 min!1,
and in D2O are 14 ± 1.5 min!1 and 8.00 ± 1.3 min!1, respectively.
Fig. 4. Steady-state kinetic solvent isotope effects observed for hydroxylase (A and
B) and lyase (C) CYP19A1 catalysis. The number on the bar represents the value of
the activity. The error bar represents the standard deviation of 3–5 independent
measurements.
Fig. 5. Conversion of 19-OH-AD to 19-oxo-AD by CYP19A1 going through dehydration of a gem-diol intermediate.
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AD 1.63 4.06 2.49 2.6 2.7 5.69 2.7
0.62 1.52 2.45 2.14
19-OH AD 2.30 1.80 0.78 1.0 2.0 4.10 1.2
2.39 0.91 0.38 3.30
19-oxo-AD 7.10 – 2.5 7.10 2.5
2.80 – 2.80
H2O/D2O.
Fig. 6. Comparison of the rates of NADPH oxidation (nmol NADPH/min/nmol p450) (solid bar) and coupling efficiency (%) (open bar) during CYP19A1 catalysis in H2O (A) and
D2O (B). The error bar represents the standard deviation of 3–5 independent measurements.
3120 Y. Khatri et al. / FEBS Letters 588 (2014) 3117–3122
	 87	
limiting resulting in a diminished KSIE for 19-oxo-AD formation and giving rise to a smaller observed 
KSIE with respect to total product for step II as compared to steps I and III of CYP19A1 catalysis. It is 
noteworthy that the formation of estrone from 19-OH-AD shows a KSIE >2, which is consistent with 
other data.  
 
 
Figure 6.3: CYP19A1 mediated conversion of 19-OH-AD to 19-oxo-AD by dehydration of a 
geminal-diol at C-19 position formed following the hydroxylation steps I and II. 
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noteworthy that the formation of estrone from 19-OH-AD shows
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the polar nature of these substrates thereby making possible presence of additional water molecules 





Figure 6.4: Rates of NADPH consumption (black bars) and coupling efficiency (white bars) 
during CYP19A1 mediated catalysis of AD, 19-OH-AD and 19-oxo-AD in protiated buffer system 
(A); Rates of NADPH consumption (black bars) and coupling efficiency (white bars) during 
CYP19A1 mediated catalysis of AD, 19-OH-AD and 19-oxo-AD in deuterated buffer system (B). 
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rise to a smaller observed KSIE with respect to total product for
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1991; Shimada et al., 1997). The presence of kinetic solvent isotope effect of a similar magnitude 
when 19-oxo-AD, the substrate for lyase step of CYP19A1, suggests the involvement of the Cpd I 
intermediate for this reaction as well. In addition, CYP19A1 also showed the highest coupling for the 
lyase substrate, 19-oxo-AD, compared with the hydroxylase substrates, AD and 19-OH-AD, in both 
protiated and deuterated solvent system.  
Taken together, our results suggest that the involvement of the same high-valent iron-oxo species, 
Cpd I, as the reactive intermediate during the conversion of AD, 19-OH-AD and 19-oxo-AD. This is 
based on the significant KSIE observed during the first two steps of hydroxylation as well as the last 
step of lyase reaction. Our conclusions are also in line with the suggestion, albeit indirect, of Cpd I 
mediated C–C scission by CYP19A1 provided by the rR characterization of the oxy-complexes of AD 
and 19-oxo-AD bound CYP19A1 in Nanodiscs. This is in stark contrast to our results with human 






CYP17A1 and CYP19A1 are the key cytochrome P450 enzymes involved in hormone biosynthesis in 
humans. While CYP17A1 is responsible for synthesizing androgens from the precursors progesterone 
and pregnenolone, CYP19A1 acts on the androgens to produce estrogens. Both these enzymes 
attract special interest because in addition to catalyzing conventional hydroxylation reactions, they 
also mediate scission of carbon-carbon bonds. The mechanism and modulation of these lyase 
reactions is of significant interest in efforts for drug development to target hyper-activation of both 
these P450s, but has remained elusive so far.  
During my thesis research, I have tried to answer some of these important mechanistic questions. By 
determining kinetic solvent isotope effects on the product formation rates for CYP17A1 mediated 
formation of AD from OH-PROG, I was able to show that this reaction follows a proton independent 
mechanism. Using cryo-radiolytic reduction and thermal annealing to follow reaction intermediates, I 
observed that unlike the hydroxylation reactions, during CYP17A1 catalyzed AD formation, a new 
intermediate appeared following the peroxo-anion species. By employing resonance Raman 
spectroscopy on thermally annealed samples, we were able to deduce that the new intermediate is a 
peroxo-hemiketal, similar to the intermediate previously discovered in OH-PREG catalysis by (Mak et 
al., 2015).  
A very important aspect of CYP17A1 mediated androgen synthesis is the selective modulation of the 
lyase reaction by cyt b5. Whether cyt b5 acts only as an allosteric effector, or if it acts as an electron 
donor has been a subject of intense debate and controversy. In order to answer this question, I 
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prepared redox inactive form of cyt b5 in which the heme iron was substituted with manganese (Mn 
b5). I observed that unlike cyt b5, Mn b5 was unable to stimulate product formation with either of the 
lyase substrates. This clearly suggests that for cyt b5 mediated stimulation of CYP17A1 mediated 
androgen synthesis, the electron transfer ability of the former is crucial.  
In order to probe any allosteric effects associated with cyt b5 binding, we used resonance Raman 
spectroscopy on substrate bound ferric and oxy-ferrous CYP17A1 in complex with Mn b5, which was 
used to avoid spectral overlap from heme of cyt b5. Mn b5 binding to ferric CYP17A1 failed to induce 
any significant changes in the heme vibrational modes or the active site. However, the axial Fe-S 
bond was observed to be strengthened in ferric CYP17A1 in complex with Mn b5. When rR 
measurements were done on oxy-ferrous CYP17A1 in complex with Mn b5 and bound to OH-PREG, 
the spectra appeared similar to those when no Mn b5 was present. It should be recalled that previous 
rR studies with OH-PREG and OH-PROG bound oxy-ferrous CYP17A1 performed by (Gregory et al., 
2013) show that in the absence of any cyt b5, there is a hydrogen bonding interactions between the 
substrate 17-OH group and dioxygen ligand of the heme.  
In the case of OH-PREG, the 17-OH group donates a hydrogen bond to the proximal oxygen atom, 
whereas 17-OH group of OH-PROG is involved in a hydrogen bond with the distal oxygen of the 
Fe-O-O of the P450. Taken together, it follows that for OH-PREG catalysis, cyt b5 enhances the rate 
of DHEA product formation solely on account of its redox donor role. On the other hand, similar rR 
experiments with OH-PROG bound oxy-ferrous CYP17A1 in complex with Mn b5 showed partial 
conversion to a conformer in which the 17-OH group of the substrate was involved in hydrogen bond 
with the proximal oxygen atom. This orientation of substrate is most conducive for the distal oxygen 
of the peroxo-anion to initiate nucleophilic attack on the C-20, thereby giving rise to the peroxo-
hemiketal intermediate. Therefore, in addition to the aforementioned redox role, cyt b5 also exerts 
subtle conformational changes which are dependent on the identity of the substrate in the active site. 
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In order to investigate how the electron transfer role of cyt b5 stimulates OH-PREG turnover to DHEA, 
we measured reduction rates of substrate bound oxy-ferrous CYP17A1 by CPR and by cyt b5 using a 
stopped flow setup. We determined that cyt b5 reduces OH-PREG bound oxy-complex 10-fold faster 
than CPR, and in a ternary complex, the reduction predominantly occurs by cyt b5. The results from 
the CYP17A1 study can be summarized in a simplified version as Figure 7.1. 
Upon investigation of kinetic solvent isotope effects on the product formation rates for CYP19A1 
catalyzed synthesis of estrogens from androgen substrates, I observed that unlike CYP17A1, 
CYP19A1 lyase reaction proceeds through the proton dependent compound I pathway. 
In a nutshell, while CYP17A1 follows different mechanistic pathways for carrying out different reaction 
chemistries in the same active site, CYP19A1 employs the same intermediate for all its reactions. 
Cytochrome b5 mediated modulation of CYP17A1 lyase step requires a critical redox transfer from the 
former, and cyt b5 reduces oxy-complex 10 times faster than the reduction rate by CPR. Furthermore, 
while we observed subtle conformational changes associated with this interaction, they are strictly 




Figure 7.1: Updated P450 reaction cycle for CYP17A1 catalysis. Black arrows represent the 
canonical Cpd I mediated hydroxylation reaction and red arrows depict the lyase reaction 
mechanism involving the new peroxo-hemiketal intermediate formed as a result of the peroxo-
anion mediaetd nucleophilic attack on carbonyl 20 of lyase susbtrates. Also shown is the 
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